initi coverag outperform
initi coverag clinical-stag biotechnolog
compani develop mrna address infecti diseas cancer rare
diseas outperform rate month target price anticip
commerci first development-stag drug
uniqu compani develop messeng rna mrna
therapeut agent establish proof-of-concept technolog
high-difficulti set
set may econom attract establish
platform overcom numer obstacl mrna
therapi previous encount includ deliveri target site
potenc advers event inflamm necrosi
mrna eleg way treat diseas provid patient
instruct set make his/her drug make replac protein
mrna essenti softwar life
make mrna potent effect advanc nanoparticl
deliveri system uniqu surfac characterist overcom deliveri
platform provid unpreced scale pace seven
short year sinc compani found advanc program
focu program detail report advanc ten compound
clinic time unpreced number time frame
biotech compani previous
year price histori
pioneer new class
medicin made messeng rna
mrna potenti implic
use mrna drug signific
far-reach found
analyst certif import disclosur see disclosur
estim first product revenu
result total revenu year million potenti
grow billion growth program
success current plan indic
estim oper loss continu product launch
compani turn profit
dilut ep expect neg turn
posit
estim need rais approxim billion
compani stage develop pre-
approv primarili focu potenti futur revenu valu
compani base expect launch
first product next six year estim moderna
total revenu increas billion howev
case development-stag compani estim
carri degre risk
pa phase i/ii data
pa ind file
mma ind file
estim sell price experiment product
low gain fda approv indic sooner
model market penetr rapid
estim would signific upsid estim
acknowledg possibl signific downsid
estim due inher risk drug develop
worst case stock could littl valu
base balanc pre-phas ii phase ii program calcul combin weight averag risk discount
potenti revenu summari appli biotech group averag price-to-sal ratio
risk discount revenu billion billion discount arriv valu billion discount invest
return year arriv valu billion per share
believ success next sever year highli depend posit clinic data fda approv
launch current experiment clinic compound biggest risk product candid gain fda approv
therefor becom commerci product gain fda approv risk includ manufactur secur
favor price third parti reimburs patient drug cost patient behavior physician adopt product maintain
patent protect structur chang healthcar market
tabl content
financi summari
summari potenti near-term
anticip data releas regulatori
initi coverag clinical-stag biotechnolog
compani develop mrna address infecti diseas cancer cardiovascular
rare diseas outperform rate month target price
anticip commerci first development-stag drug
compani stage develop pre-approv primarili
focu potenti futur revenu valu compani base expect
launch first product next six year estim
total revenu increas billion howev case
development-stag compani estim carri degre risk
accord proprietari databas averag forward price-to-sal
biotechnolog sector discount estim revenu billion
risk failur invest return arriv target price
howev acknowledg possibl signific downsid estim due
inher risk drug develop worst case stock
could littl valu
valuat methodolog compani depend development-stag
product meaning percentag estim futur earn base appli
industri price-to-earnings multipl price-to-earnings growth rate ratio price-to-sal multipl
estim futur earn revenu discount valu base
estim risk failur use biotechnolog group multipl deriv averag
multipl compani profit sever year exhibit defin
biotechnolog industri equal weight stock biotechnolog compani
posit earn
exhibit price-to-earn price-to-earnings price-to-earnings growth price-to-sal ratio calcul
base price group last day month consensu earn per share
estim forward year sourc data use calcul
databas compil maintain oppenheim co use estim factset price
quot servic
typic appli averag multipl futur estim revenu earn
determin discount rate base compani stage develop use risk
failur base phase develop publish tuft center studi
drug develop base data failur rate potenti drug phase
develop approxim progress phase ii develop
failur rate approxim progress phase develop
failur rate approxim actual file approv
food drug administr failur rate
pipelin ten experiment clinic therapi ten pre-
clinic candid first anticip commerci impact growth
product result product sale would account
revenu base balanc pre-phas ii program
phase ii program calcul combin weight averag risk discount
potenti revenu
summari appli biotech group averag price-to-sal ratio
risk discount revenu billion billion discount arriv
valu billion discount invest return year arriv
valu billion per share
revolutionari compani develop messeng rna mrna
therapeut agent establish proof-of-concept technolog high-
difficulti vaccin set set may econom attract
establish platform overcom numer obstacl mrna
therapi previous encount includ deliveri target site potenc
advers event inflamm necrosi
mrna eleg way treat diseas provid patient instruct set
make his/her drug make replac protein mrna essenti
softwar life semin develop work involv uridin modif
enabl compani make mrna potent effect advanc
nanoparticl deliveri system uniqu surfac characterist overcom
deliveri challeng platform provid unpreced scale pace
seven short year sinc compani found advanc program
focu program detail report advanc ten compound
clinic time unpreced number time frame biotech
pioneer new class medicin made mrna potenti
implic use mrna drug signific far-reach could transform
certain diseas treat also medicin discov
develop manufactur breadth scale speed common
biopharma industri found arguabl built industri
lead mrna technolog platform infrastructur acceler drug discoveri
speed develop develop therapeut restor protein function
enabl bodi creat therapeut protein potenti cure diseas
develop pipelin includ candid mrna-bas vaccin therapi
multipl therapeut area compani sever clinic trial way
addit number discoveri program advanc toward
could transform certain diseas treat drug discov
develop manufactur approv mrna therapeut modal could
extrem excit base potenti use human bodi abil make
protein drug diseas
ribonucl acid rna hallmark central dogma biolog central
dogma dna produc rna rna produc protein protein vast
array function within organ rna product dna transcript dna
replic second major form nucleic acid cell dna mani
function nucleic acid dna rna polym nucleotid store
transmit genet inform rna molecul structur catalyt role
supra-molecular complex
gene express rna act intermediari use inform encod
dna specifi amino acid sequenc function protein protein long polym
amino acid major compon cell polym chain fold specif
three-dimension structur determin protein activ protein
catalyt activ function enzym servic structur element signal report
transport carri specif substanc cell protein lead
perform within cell
rna essenti compon protein synthesi process convert genet
inform function protein unlik dna rna occur singl strand
human protein synthesi two-step process first step known gene
transcript segment dna use guid synthesi single-strand
messeng rna mrna nucleu exhibit
step known gene translat mrna strand exit nucleu travel
ribosom use guid specif amino acid sequenc protein
importantli everi protein cell form process mutat
dna sequenc gene result defect protein potenti lead
messeng rna one sever class cellular rna transfer rna serv
adaptor molecul protein synthesi molecul histor consid non-cod
rna translat protein product known play role mani
interf rna sirna other
ribosom rna structur compon ribozym wide varieti
special function rna includ enzymat activ
microrna small strand rna gene-specif use sequenc target
mrna bind silenc correspond express gene small
interf rna synthet model non-cod rna bind target mrna
sequenc block gene transcript messeng rna also use produc
microrna studi use therapeut agent
messeng rna also produc miss protein creat protein therapeut
therapeut mrna design produc function protein patient cell
vivo deliveri mrna long-stand goal clinic drug develop
could offer entir new way treat human diseas mrna strand
highli customiz theori deliveri protein-cod mrna diseas tissu
could replac defici aberr protein patient genet diseas
technolog could also use deliv function protein enhanc endogen
process tissu repair stimul anti-tumor immun respons similarli
mrna-bas drug could also use creat vaccin infecti diseas
cancer success mrna-bas drug potenti address diseas current
untreat modern medicin mani challeng deliv mrna
therapeut mrna larg highli unstabl molecul make difficult
deliv vivo typic mrna hundr thousand nucleotid length
significantli larger rnai aso base drug introduc challeng
synthesi packag deliveri target cell addit mrna must
design engag endogen protein synthesi machineri correct
code sequenc actual produc function protein summari mrna drug
potenti fundament chang way diseas treat present
uniqu set challeng
date fda-approv mrna therapeut mrna therapeut
develop either prophylact vaccin treatment infecti diseas
person vaccin cancer infecti diseas mrna vaccin design
encod one viral antigen inject bodi direct synthesi
correspond viral peptid peptid stimul immunogen respons
product neutral antibodi cancer person mrna vaccin
base scienc tumor-specif neoantigensantigen aris due
genet mutat uniqu tumor gener treatment involv use next-
gener tumor sequenc coupl predict algorithm identifi neoantigen
specif tumor put neoantigen engin custom mrna
vaccin design stimul anti-tumor immun respons
fda-approv mrna therapeut number compound clinic
develop shown exhibit
mrna drug
develop rna-bas therapeut wide rang human diseas
rna essenti intermediari genet inform encod dna
protein moment modern medicin lack method correct underli
genet defect therefor mani estim genet diseas lack effect
key success make mrna drug modif uridin
previous mention rna produc dna rna uracil base-pair
adenin replac thymin dna transcript uracil help carri
synthesi mani enzym necessari cell function bond ribos
phosphat methyl uracil produc thymin hypothes dna
evolutionari substitut thymin uracil increas dna stabil improv
effici dna replic rna uracil bind ribos sugar form
ribonucleosid uridin phosphat attach uridin uridin
produc uridin glycosyl pyrimidine-analog contain uracil attach
ribos ring known ribofuranos via bond one five
standard nucleosid make nucleic acid other adenosin
thymidin cytidin guanosin
found mrna effect drug need overcom
mrna vulner macrophag attach consum drug identifi
issu uridin overcam uridin modif
achiev patent grant one licens million
cellcscript base univers pennsylvania discoveri secur intellectu
properti around key piec technolog outlin appendix
diseas indicationtarget organphas developmentcompanysolid tumorscancerphas vaccinevaccinephas curevachivvaccinepreclinicalcurevacrabi virusvaccinephas cancervaccinephas syncyti viru rsv vaccinepreclinicalcurevacmelanomacancerphas melanomacancerphas breast cancercancerphas myelomacancerphas cystic fibrosislungpreclinicalethrisotc deficiencyliverpreclinicalethrishcccancerphas tcrhcccancerphas tcrperson cancer vaccinevaccinephas virusvaccinephas virusvaccinephas virusvaccinephas fibrosislungphas over-the-counter deficiencyliverpreclinicaltransl moderna
leverag fundament role mrna play protein synthesi
develop novel drug base entir mrna compani develop
proprietari method creat full-length mrna deliv patient
therapeut mrna taken cell use direct protein synthesi result
product function protein mrna highli customiz mrna-bas
therapeut could theoret design genet diseas underli
genet defect known addit technolog could also use deliv
function protein enhanc endogen process tissu repair
stimul anti-tumor immun respons current focus effort
three diseas area cancer infecti diseas cardiovascular diseas
mrna-bas therapi infecti diseas
current develop mrna-bas vaccin influenza chikungunya viru
metapneumoviru parainfluenza viru type one undisclos indic
mrna-bas vaccin design encod one respect viral antigen
inject bodi direct synthesi correspond viral peptid
subsequ peptid stimul immunoen respons product
neutral antibodi mrna-bas vaccin expect sever
key advantag tradit avian-bas vaccin base attenu
weaken viru first mrna-bas vaccin mimic nativ viral infect
host respons specif due fact viral antigen synthes
endogen mrna would lead secret antigen mhc class ii antigen
present second mrna-bas vaccin produc entir vitro
avoid issu associ vaccin produc bacteria anim cell line
mrna-bas therapi cancer
cancer develop program divid two categori person
cancer vaccin intratumor immune-oncolog therapeut person
cancer vaccin program base foundat scienc tumor-specif
neoantigen neoantigen attract therapeut target specif
patient tumor mutat present tumor normal cell
potenti form immunogen antigen exclus tumor therefor
reduc risk therapy-induc autoimmun off-target effect neoantigen
identifi routin tumor biopsi sampl current compani field use
tumor biopsi collect genom dna biopsi alreadi part routin
diagnost workup mani solid tumor procedur would creat addit
patient burden addit next-gener sequenc longer cost-prohibit
process howev predict immunogen tumor antigen trivial exercis
predict immunogen neoantigen easili manufactur packag inject
patient potenti combin exist immun oncolog
therapi tumor neoantigen demonstr enhanc anti-tumor cell
activ neoantigen target approach may potenti combin
exist immunotherapi approach includ bi-specif antibodi bite/dart
specif plan use mrna encod predict immunogen neoantigen
stimul anti-tumor immun respons mrna highli customiz
approach design custom-engin patient separ moderna
intratumor immune-oncolog program base inject mrna tumor
induc express immune-stimulatori protein advanc
program ligand potent stimul cell activ
mrna-bas therapi cardiovascular diseas
evalu mrna-bas drug cardiovascular diseas rare diseas
lead program mrna vascular endotheli growth factor-a vegfa key
stimul vessel growth repair preclin data demonstr express
vegfa lead creation new blood vessel may effect
patient heart failur compromis vasculatur
lipid nanoparticl lnp deliveri system design deliv mrna
molecul specif tissu mrna deliv direct
inject tissu salin formul without lnp local produc small amount
pharmacolog activ protein techniqu use intratumor
immuno-oncolog program set result human blood fluid
contain rna degrad enzym lnp need deliveri cell membran act
signific barrier entri larg neg charg molecul mrna
develop deliveri scienc includ lnp technolog altern
nanoparticl approach enabl deliveri larger quantiti mrna target tissu
lnp gener compos four compon amino lipid phospholipid
cholesterol pegylated-lipid peg-lipid compon overal
composit contribut properti lnp system lnp deliv mrna
rapidli bind protein drive uptak lnp cell intern
endosom within cell lnp design escap endosom releas
mrna cargo cell cytoplasm mrna translat make
protein mrna lnp compon escap endosom typic
deliv lysosom degrad cellular digest
develop proprietari lnp formul address step mrna
deliveri includ cell uptak endosom escap subsequ lipid metabol
avoid counterproduct interact immun system initi
use lnp formul base known lipid system legaci lnp
overcom known limit inflammatori reaction legaci lnp design
proprietari lnp system highli toler minim lnp vehicle-rel
toxic repeat administr vivo new lnp engin amino
lipid avoid immun system meaning higher biodegrad rel
prior lipid administ intraven non-human primat nhp
mg/kg proprietari lnp demonstr rapid clearanc lipid plasma
organ hour post-administr
demonstr preclin studi maintain desir immun
respons vaccin reduc undesir local immun reaction
reactogen lnp result reduc elimin
undesir surfac featur upon repeat dose tradit lnp surfac featur
includ amino lipid phospholipid peg-lipid recogn immun
system lead rapid clearanc bloodstream decreas potenc upon
repeat dose increas inflamm
base insight mechan improv surfac characterist
proprieti lnp abl repeat-dos neglig
undetect loss potenc liver damag immun system activ
repres histolog section muscl stain hematoxalin eosin two
day singl intramuscular administr rat demonstr less inflamm
muscl cell necrosi proprietari lnp vs legaci lnp contain mg
moderna mrna compar necrosi degener muscl cell
inflamm observ legaci lnp proprietari lnp inflamm
muscl cell necrosi less extens serum cytokin level lower
importantli demonstr intraven administr six-fold
improv protein product prior state-of-the-art lnp
financi summari outlook
estim first product revenu result
total revenu year million potenti grow billion
moderna growth program success current plan indic
estim oper loss continu launch first
compound compani turn profit revenu start
meaning off-set loss dilut ep expect neg turn
posit estim need rais approxim billion
fund program current estim launch first six
summari potenti near-term product
current ten experiment clinic compound develop
three ind-en studi seven lead optim program clinic
compound includ four proof-of-concept program six program
character growth product potenti impact futur
three proof-of-concept program influenza zika
program expect econom impact importantli
demonstr abil design manufactur effect deliveri safe treat
patient mrna vaccin growth product clinic develop
potenti combin estim sale billion addit moderna
three program ind-en studi potenti combin
sale billion five advanc preclin program potenti
combin sale billion
estim clinic stage product could account billion
total estim product sale product includ growth
vegf
prophylact vaccin respiratori syncyti viru rsv design
manufactur collabor merck sale estim base market entri
detail expect drug section
report appendix estim world-wide rsv sale
increas billion
design manufactur prevent congenit cytomegaloviru cmv
infect sale estim base market entri detail
expect drug section report appendix
estim world-wide cmv vaccin sale increas billion
combin prophylact vaccin hmpv design
manufactur consist two distinct mrna sequenc encod membran
protein prevent treat infant toddler detail expect
drug section report appendix sale estim
base market entri estim world-wide sale
increas billion
person neoantigen vaccin design
manufactur includ immunogen antigen select present patient
tumor detail section report appendix
sale estim base market entri estim world-wide pcv
sale increas billion make largest contributor moderna
sale account sale
t-cell co-stimul consist mrna code ligand
detail section report appendix
estim sale anticip patient transfer
potent angiogen factor promot growth blood vessel
design manufactur collabor astrazeneca treat ischem heart
failur detail expect section appendix
sale estim base market entri estim world-wide vegf-a
sale increas billion
product expect enter clinic soon
estim product current ind-en studi could account
billion total estim product sale product
includ growth portfolio kra
kra vaccin prevent treatment solid tumor cancer
kra frequent mutat oncogen epitheli cancer includ lung colorect
pancreat cancer detail expect drug
section appendix sale estim base market entri
nsclc pancreat cancer set estim world-wide mrk-
kra vaccin sale increas billion
medi mrna deliv via intratumor inject
treatment advanc metastat solid tumor combin checkpoint
inhibitor detail expect drug section
appendix sale estim base market entri mtnbc
head neck cancer second-lin melanoma set estim world-wide
sale increas billion
t-cell co-stimul consist triplet mrna encod human
interleukin interleukin gamma administ
intratumor detail expect drug section
report appendix sale estim base market entri
mtnbc head neck cancer second-lin melanoma set estim
world-wide increas billion
estim product preclin develop could account billion
total estim product sale product includ
preclin system secret protein therapi fabri diseas
relaxin heart failur system intracellular therapi mma
pku pa
therapi treatment fabri diseas design
manufactur contain mrna encod human -gal expect mrna-
detail section report appendix sale
estim base market entri fabri diseas set start
estim world-wide sale increas million
mrna encod human relaxin protein design engin
extend half-lif treatment acut heart failur expect
detail section report appendix sale
estim base market entri heart failur set estim
world-wide sale increas billion make second
largest contributor sale sale
intraven administ mrna encod mut restor
defici defect mitochondri enzym liver caus isol methylmalon
acidemia mma expect therapi detail section
report appendix sale estim base market entri
estim world-wide sale increas million
intraven administ mrna encod phenylalanin
hydroxylas pah protein liver treatment phenylketonuria pku
expect therapi detail section report appendix
sale estim base market entri estim world-wide
sale increas billion
intraven administ combin mrna subunit
pcc pcca pccb treatment propion acidemia pa expect
therapi detail section report appendix sale
estim base market entri estim world-wide
sale increas million
compani websit sec file
mrna-bas vaccin treatment cytomegaloviru cmv
evalu phase studi detail inform
appendix
mrna mrna-bas vaccin treatment respiratori syncyti
viru rsv current evalu phase studi collabor merck
detail inform appendix
mrna-bas vaccin treatment chikungunya viru
current evalu phase studi healthi volunt detail inform
appendix
mrna-bas vaccin treatment human metapneumoviru
hmpv parainfluenza viru current evalu
phase ib studi detail inform appendix
mrna-bas person cancer vaccin treatment variou
cancer current evalu phase studi candid develop
collabor merck detail inform appendix
mrna-bas therapeut vaccin treatment kras-posit
tumor ind file phase plan initi detail inform
appendix
mrna ligand current evalu phase
studi detail inform appendix
mrna program complet glp
toxic studi ind file detail inform
cardiovascular diseas diseas
mrna vascular endotheli growth factor-a vegf-a program
develop collabor astrazeneca current phase ii clinic
studi patient undergo cabg procedur detail inform
mrna therapeut treatment methylmalon acidemia mma
program evalu phase i/ii studi detail inform
appendix
mrna-bas vaccin treatment influenza subtyp
current phase studi expect complet detail inform
appendix
mrna-bas vaccin treatment influenza subtyp
current evalu phase studi healthi volunt detail inform
appendix
mrna-bas vaccin treatment zika viru current
evalu phase i/ii studi healthi volunt detail inform mrna-
appendix
mrna-bas vaccin treatment zika viru program
yet evalu glp toxic studi
mrna-bas vaccin treatment undisclos
infecti diseas develop collabor merck
medi mrna program develop collabor
astrazeneca complet glp toxic studi detail inform
appendix
cardiovascular diseas diseas
therapi treatment fabri diseas conduct
preclin studi evalu plan conduct open-label phase i/ii
clinic trial multipl ascend dose evalu safeti efficaci mrna-
patient detail inform appendix
mrna encod human relaxin protein design engin
extend half-lif treatment acut heart failur conduct
preclin studi rodent non-human primat nhp observ
relaxin mrna give rise long-last system function protein follow
intraven dose detail inform appendix
mrna encod phenylalanin hydroxylas pah protein
treatment phenylketonuria pku plan conduct phase open-label
clinic trial singl ascend dose evalu safeti toler activ
develop candid patient detail inform
intraven iv -administ combin mrna subunit
pcc pcca pccb encapsul lipid nanoparticl lnp treatment
propion acidemia pa current conduct global natur histori studi
mma pa plan initi phase i/ii clinic trial pediatr pa patient
detail inform appendix
anticip data releas fda file
base current pipelin new entiti summar
expect data news releas exhibit
exhibit expect data news releas base compani inform calcul base studi
base current pipelin preclin entiti summar
expect regulatori file exhibit
exhibit expect regulatori file base calcul typic preclin activ timelin oppenheim
product candidateindicationstudyexpect time proceduresphas ii month post-trial i/ii plan candidateindicationstudyfilingexpect time month post-glp toxicolog studi month post-glp toxicolog studi month post-glp toxicolog studi outperform
manag board
continu next page
name officerag salari bonu option award stock award compens total experi summary/ career highlightsstphan bancel chief execut mr stphane bancel join summer one employe compani assembl world-class team rais nearli billion equiti financ up-front licens collabor previous ceo biomrieux world leader diagnost industri biomerieux employe market capit billion sale billion prior time biomrieux mr bancel manag director belgium execut director global manufactur strategi suppli chain indianapoli indiana start lilli uk manufactur plant outsid london hold master engin cole central pari master scienc chemic engin univers minnesota harvard busi school mr bancel elect young global leader world econom forum elect best ceo investor relat franc rank number one ceo biotech sector accord thomson reuter extel studi mr bancel serv supervisori director qiagen board director syro pharmaceut stephen hoge presid dr stephen hoge lead research develop mrna technolog includ chemistri biolog formul technic develop addit stephen respons new ventur lab intern ventur incub play found role therapeut area ventur join earli stage dr hoge play wide rang role compani includ lead corpor develop strategi mrna scienc preclin oncolog prior dr hoge partner mckinsey compani leader firm healthcar practic mckinsey dr hoge advis senior manag team lead biotech pharmaceut compani wide rang strateg oper topic prior join mckinsey dr hoge physician new york hold thesi univers california san francisco neurosci amherst colleg current dr hoge also serv board director axcella inc clinic stage biotechnolog compani juan andr senior vice presid late stage technic develop senior vice presid late stage technic develop manufactur mr juan andr respons scale-up manufactur qualiti effort prepar bring gmp mrna clinic manufactur on-line also lead effort prepar phase develop commerci mr andr previous global head technic oper manufactur suppli chain novarti employe across divis role respons novarti manufactur site relat support function technolog world-wide overse small molecul drug substanc drug product well biolog drug substanc drug product technic develop mr andr previou role novarti includ group novarti qualiti head global head technic research develop global pharmaceut oper head prior novarti mr andr work co year varieti manufactur product qualiti role unit state puerto rico uk spain recent serv vice presid pharmaceut manufactur mr andr hold undergradu degre pharmaci alcala de henar univers madrid complet advanc develop program london busi school
continu next page
name officerag salari bonu option award stock award compens total experi summary/ career highlightsmarcello damiani chief digit chief digit offic mr marcello damiani bring wealth experi compani life scienc compani true passion make digit realiti year experi work field last year spent leadership role multi-national compani europ prior join mr damiani instrument conceiv build creativ solut help solv busi challeng first motorola biomerieux expertis vision strateg implement innov program updat streamlin digit landscap known abil transform compani inform flow ultim improv product compani process digit mr damiani possess master scienc degre inform system architectur univers toulous franc finish intern execut program trium allianc three world top univers london school econom new york univers stern busi school hec school manag pari anni seibold drapeau chief anni seibold drapeau serv chief offic lead compani talent organiz strategi prior join ms drapeau serv oper bain capit privat equiti partner compani across privat equiti portfolio rang talent organiz capabl initi previous ms drapeau serv execut vice presid strategi billion data storag protect busi nearli employe world-wide respons corpor strategi human resourc compani portfolio emerg busi opportun also led compani divers sustain effort join ms drapeau held leadership role human resourc strategi financ center lead organ vistaprint digita jpmorgan ms drapeau publish theharvard busi reviewon topic trust leadership also led session topic annual meet world econom forum davo ms drapeau hold bachelor chemic engin bucknel univers amo tuck school dartmouth colleg chair boston advisori board director poss foundat sit alumni associ board director bucknel univers truste nashoba brook school lori henderson gener counsel corpor gener counsel corpor secretari sinc april ms henderson lead legal govern corpor complianc effort come nearli year corpor attorney law firm gener counsel role guid global public privat compani ms henderson deep busi develop regulatori govern experi work extens execut leadership team public privat compani came albani molecular research amri waltham-bas pharmaceut contract research manufactur organ senior vice presid gener counsel corpor secretari head busi develop led global legal busi develop function extens involv pharmaceut licens partner acquisit integr multipl compani ultim sale compani privat equiti late prior amri gener counsel corpor secretari chief administr offic rand world-wide technolog sale servic organ prior gener counsel corpor secretari chief administr offic moldflow corpor sold start career corpor practic boston law firm goodwin procter ms henderson receiv juri doctor georg washington univers law school gordon colleg outperform
continu next page
name officerag salari bonu option award stock award compens total experi summary/ career highlightsstephen harbin senior vice presid manufactur operationsmr stephen harbin bring year divers oper experi pharmaceut in-vitro diagnost posit serv varieti senior busi oper leadership role europ prior join corpor vice presid global oper biomrieux respons global employe multipl global function manufactur site career mr harbin held senior leadership posit drive strateg direct perform area manufactur inform system qualiti regulatori affair complianc continu refin reengin intern process drive transform respons new busi challeng mr harbin held leadership role eli lilli compani shionogi qualicap spain elanco qualicap work cover mani differ dimens sale market hr peopl develop highli regul environ result receiv best practic recognit fda graduat durham colleg agricultur uk saqib islam chief busi officera chief busi offic mr saqib islam overse critic aspect growth includ global strateg plan corpor develop busi develop mr islam join fromalexion pharmaceut serv execut vice presid chief strategi portfolio offic execut compani corpor growth strategi contribut assess manag global oper prior join alexion mr islam work year intern busi manag focu busi develop strateg decision-mak plan capit market extens background healthcar bank sector held posit increas respons invest bank divis merril lynch recent credit suiss secur earlier career mr islam provid strateg analysi advic client firm across divers industri segment boston consult group mr islam receiv bachelor degre mcgill univers graduat univers scholar columbia law school harlan fisk stone scholar jame kasing gener counselmr jim kasing lead legal corpor govern intellectu properti matter highli accomplish attorney year experi mr kasing bring extens background corpor law merger acquisit secur licens law join mr kasing gener counsel plumchoic inc provid technic support servic fortun compani prior plumchoic mr kasing partner global law firm goodwin procter llp repres life scienc technolog high-growth compani stage life cycl format obtain seed growth financ initi public offer merger sale mr kasing start legal career testa hurwitz thibeault mr kasing hold jd boston colleg law school graduatingcum laud wheaton colleg graduatingmagna cum laud john mendlein ph presid corpor product mendlein ph serv presid corpor product strategi sinc januari march june dr mendlein serv member board director serv differ senior board role includ execut chairman chief execut offic gener counsel variou biotechnolog compani includ acquir debiopharm group acquir bm atyr pharma inc life atyr aurora bioscienc acquir vertex also serv atyr chief execut offic current serv atyr board vice chairman board dr mendlein author inventor public patent dr mendlein hold ph physiolog biophys univers california lo angel univers california hast colleg law biolog univers miami
continu next page
name officerag salari bonu option award stock award compens total experi summary/ career highlightslor chief dr lorenc join goldman sach manag director co-head biotechnolog invest bank effort join goldman sach summer associ name manag director member healthcar invest bank group nearli year dr respons includ corpor financ merger acquisit pharmaceut biotechnolog industri sever billion equiti equity-link financ billion transact dr current member board director ofser prior join goldman sach dr work variou medic research consult posit concurr graduat studi dr graduat harvard univers magna cum laudeand phi beta kappa biochem scienc also earn healthcar manag palmer scholar wharton school univers pennsylvania univers pennsylvania school medicin pace chief corpor affair pace serv chief corpor affair offic sinc april februari decemb ms pace held senior posit includ senior vice presid strateg oper pkr program execut may januari held senior posit includ senior vice presid corpor commun ms pace receiv colleg charleston melissa moor ph chief scientif offic mrna research platformin role chief scientif offic mrna research platform dr melissa moor respons lead mrna biolog research join univers massachusett medic school umm serv professor biochemistri molecular pharmacolog eleanor eusti farrington chair cancer research investig howard hugh medic institut hhmi dr moor also found co-director rna institut rti umm instrument creation massachusett therapeut entrepreneurship realiz initi massteri faculty-l program intend facilit translat umm discoveri drug product technolog compani dr moor research umm hhmi encompass broad array topic relat role rna rna-protein rnp complex gene express touch mani human diseas includ cancer neurodegener preeclampsia prior umm spent year professor brandei univers began work rna postdoctor train phillip sharp ph institut professor koch institut integr cancer research mit also receiv ph biolog chemistri dr moor hold chemistri biolog colleg william mari upon join dr moor retain academ affili umm part-tim faculti member outperform
continu next page
name officerag salari bonu option award stock award compens total experi summary/ career highlightsgiusepp ciaramella ph chief scientif offic infecti diseasegiusepp ciaramella ph chief scientif offic infecti diseas join januari vice presid immunolog serv cso infecti diseas effort sinc octob dr ciaramella year drug discoveri experienc astrazeneca boehring ingelheim merck hel sever leadership role particular focu field antivir immunolog biotherapeut prior join led small molecul antivir strategi astrazeneca boehring ingelheim vice presid head collabor research respons extern member ww research leadership prior boehring ingelheim dr ciaramella spent year uk held sever discoveri leadership posi tion includ head head antivir head lead discoveri career contribut sever clinic candid small mole cule biolog anti-hiv drug maraviroc selzentri tm usa prix galien best pharmaceut dr ciaramella hold phd biochemistri molecular biolog univers colleg london fellow royal societi chemistr uk member infecti diseas societi america idsa paolo martini ph chief scientif offic diseasespaolo martini ph chief scientif offic diseas year experi drug discoveri work molecular mechan underli monogen multigen metabol fibrot disord well hematolog malign dr martini laboratori focus identifi novel therapi appli translat approach drug develop rare genet disord previous dr martini work shire plc lexington mass senior director discoveri biolog mass focus fibrot diseas muscl kidney skin lung bone marrow metabol liver diseas particular emphasi differ therapeut modal pathway modul role shire support phase clinic studi lysosom storag chronic kidney diseas prior shire dr martini work emd-serono five year discoveri research graduat univers milan itali move germani post-doctor work schere ag bayer berlin germani univers illinoi urbana champaign dr martini collabor organ support research clinic develop rare metabol disord fibrot diseas former scientif advisori board member keyston symposia tal zak ph chief medic chief medic offic dr tal zak overse preclin develop clinic develop regulatori affair across ventur prior join dr zak senior vice presid head global oncolog sanofi respons aspect oncolog drug discoveri develop commerci dr zak began industri career glaxosmithklin genet research group built oncolog translat medicin team led translat research lapatinib well in-licens clinic develop foretinib addit industri work dr zak associ professor medicin univers pennsylvania serv volunt physician philadelphia veteran administr medic center treat patient genitourinari cancer dr zak receiv ph gurion univers israel conduct post-doctor research nation institut complet clinic train intern medicin templ univers hospit follow fellowship medic oncolog univers pennsylvania dr zak serv board director adaptimmun plc comment larg highli experienc manag team breadth talent
continu next page
board directorsag director salari option award stock award total affiliation/car highlightsnoubar afeyan ph co-found chairman ceo flagship dr noubar afeyan co-found chairman ceo flagship pioneer lead earli stage ventur capit firm also lead firm venturelab unit invent launch transform startup senior lectur mit sloan school manag taught cours technolog entrepreneurship innov leadership sinc dr afeyan author numer scientif public patent sinc earn ph biochem engin mit lectur wide unit state intern divers topic rang entrepreneurship innov ventur capit biolog engin drug discoveri medic technolog renew energi career inventor entrepreneur ceo ventur capitalist dr afeyan co-found help build success life scienc technolog startup current dr afeyan serv number public privat compani board addit member sever advisori board includ yale climat energi initi skolkovo school manag moscow also member board overs boston symphoni orchestra previous founder ceo persept biosystem leader bio-instrument field grew million annual sale within six year first sale member found team director investor sever highli success ventur includ acquir millennium pharmaceut color kinet acquir philip acquir bristol-my squibb stphane bancel chief execut stphane bancel join summer one employe compani assembl world-class team rais nearli billion equiti financ up-front licens collabor previous ceo biomrieux world leader diagnost industri biomerieux employe market capit billion sale billion prior time biomrieux mr bancel manag director belgium execut director global manufactur strategi suppli chain indianapoli indiana start lilli uk manufactur plant outsid london hold master engin cole central pari master scienc chemic engin univers minnesota harvard busi school mr bancel elect young global leader world econom forum elect best ceo investor relat franc rank number one ceo biotech sector accord thomson reuter extel studi mr bancel serv supervisori director qiagen board director syro pharmaceut outperform
continu next page
board directorsag director salari option award stock award total affiliation/car highlightspet barton hutt senior counsel covington peter barton hutt senior counsel washington dc law firm covington burl special food drug law chief counsel food drug administr fda sinc taught full cours food drug law winter term harvard law school taught cours stanford law school spring term co-author food drug law case materi publish book chapter articl food drug law health polici repres nation trade associ food prescript drug nonprescript drug dietari supplement cosmet industri fda draft legisl becam medic devic amend begin particip draft major legisl amend feder food drug cosmet act testifi hous senat time either counsel accompani wit wit mr hutt member institut medicin iom nation academi scienc na sinc form serv iom execut committe na iom committe recent serv member work group innov drug develop evalu presid obama council advisor scienc technolog pcast scienc review subcommitte fda scienc board review fda scienc need order perform regulatori mission panel administr restructur nation institut work group review regulatori activ within divis aid nation institut allergi infecti diseas member board director aera global tb vaccin foundat foundat biomed research california care institut institut polici analysi keck graduat institut appli life scienc one claremont colleg stephen berenson manag flagship stephen berenson manag partner flagship pioneer member firm invest manag committe focus capit format fund portfolio compani level help firm manag team grow realiz valu stephen also drive strateg oper improv across firm portfolio compani help deepen relationship critic extern partner stephen join flagship career invest banker morgan time work across major geographi product area industri group key player build bank equiti technolog invest bank busi last twelv year morgan stephen vice chairman invest bank focus provid high-touch strateg advic complex transact execut lead compani across industri global co-found morgan global strateg advisori council co-found firm board initi stephen leadership board initi independ director public compani attend least one morgan board event discuss debat share best practic key issu face fulfil duti stephen also made import contribut morgan cultur deep support recruit train develop mentor help build maintain robust control environ particip firm equiti underwrit reput risk committe stephen graduat mit mathemat member board truste mahaiw perform art center great barrington massachusett
continu next page
board directorsag director salari option award stock award total affiliation/car highlightsrobert langer sc academ co-found david koch institut professor robert langer david koch institut professor mit dr langer written articl also approxim issu pend patent world-wide dr langer patent licens sublicens pharmaceut chemic biotechnolog medic devic compani cite engin histori serv member fda scienc board fda highest advisori board chairman dr langer receiv major award includ unit state nation medal scienc charl stark draper prize consid equival nobel prize engin millennium prize world largest technolog prize priestley medal highest award american chemic societi also engin receiv gairdner foundat intern award recipi award subsequ receiv nobel prize among numer award langer receiv dickson prize scienc heinz award technolog economi employ harvey prize john fritz award given previous inventor thoma edison orvil wright ketter prize cancer research david prize materi scienc albani medic center prize medicin biomed research largest prize medic research induct nation inventor fame max planck research award princ asturia award technic scientif research receiv lemelson-mit prize world largest prize invent one histori prolif inventor medicin dr langer elect institut medicin nation academi scienc elect nation academi engin nation academi scienc one peopl ever elect three unit state nation academi youngest histori age ever receiv distinct john mendlein ph execut chairman ceo atyr dr john mendlein execut chairman ceo atyr pharma novel protein therapeut vice chairman drug stem cell two privat held biotech compani san diego prior involv enterpris serv ceo adnexu pioneer new class protein therapeut purchas bristol-my squibb compani million previous dr mendlein serv chairman ceo inc serv varieti role includ board member gener counsel chief knowledg offic aurora bioscienc acquir biotechnolog compani focus discov drug ion channel includ cftr led discoveri breakthrough medicin kaledyco approv cystic fibrosi dr mendlein work smith kline french glaxosmithklin gsk scientist depart molecular biolog protein express cooley llp law firm attorney life scienc technolog litig practic group serv board member monogram bioscienc mgrm acquir lab corp lh current advisori board member genesi capit ventur capit firm canada founder board member home sudan profit boston scientif advisori board member ocean discoveri institut profit san diego dr mendlein author inventor public patent variou award work biotechnolog scienc well write-up variou busi endeavor wall street journal financi time newsweek dr mendlein earn ph physiolog biophys univers california lo angel jd univers california hast school law biolog univers miami outperform
continu next page
board directorsag director salari option award stock award total affiliation/ highlightselizabeth nabel presid harvard-affili brigham women health nabel serv presid harvard-affili brigham women health bwhc sinc cardiologist distinguish biomed research nabel professor medicin harvard medic school nabel work molecular genet cardiovascular diseas produc patent scientif public nabel scientif contribut cardiovascular gene transfer develop molecular cellular techniqu delin pathophysiolog atherosclerosi clarifi process cell divis growth vascular smooth muscl cell blood vessel studi hutchinson-gilford progeria syndrom character vascular smooth muscl cell defect lead prematur heart attack stroke colleagu elect american academi art scienc nation academi medicin associ american physician american societi clinic investig fellow american associ advanc scienc nabel serv board medtron broad institut howard hugh medic institut partner health ariadn lab previous serv editori board thenew england journal medicineandsci translat medicinea well editor-in-chief ofscientif american medicin nativ st paul minnesota nabel attend weill cornel medic colleg complet intern medicin cardiolog train brigham women hospit israel ruiz audit committe chair execut vice presid treasur massachusett institut israel ruiz execut vice presid treasur massachusett institut technolog mit serv audit committe chair board director mit chief offic truste mit corpor member execut committe mr ruiz chief steward billion financi asset billion oper revenu respons administ mit billion capit plan mit mr ruiz respons financi debt strategi develop budget capit plan integr financi inform area respons includ human resourc inform system campu facil secur safeti complianc govern relat intern support sustain medic prior becom execut vice presid treasur mr ruiz held sever role increas respons mit recent serv vice presid financ mr ruiz previous held manag engin role hewlett-packard nissan automot mr ruiz instrument lead re-zon effort kendal squar cambridg mass enabl mixed-us develop acceler process move idea lab market continu activ co-lead develop process complex execut phase expect last beyond mr ruiz serv board director edx mit harvard on-lin learn initi mit endicott hous mit technolog review mit engin serv audit committe chair board director nyse spin-out nyse also director govern board eliot innov school activ boston public school mr ruiz hold master degre mit sloan school manag six-year degre industri mechan engin polytechn univers catalonia nativ barcelona
sec file compani websit
board directorsag director salari option award stock award total affiliation/car highlightspaul sagan manag director gener sagan manag director ventur capit firm gener catalyst focus invest internet softwar servic infrastructur compani previous execut resid xir firm prior join gener catalyst mr sagan ceo pioneer internet content deliveri applic perform cloud secur one largest cloud servic provid join akamai octob chief oper offic becam presid follow year ceo april mr sagan elect akamai board director januari continu serv mr sagan also director vmware inc catalina lab privately-held compani previous serv director irobot corp well jone compani acquir news corp digita inc acquir publici group emc corp acquir maven network acquir yahoo mr sagan began career televis journalist work recogn three emmi award broadcast news new york citi later join time warner co-found three busi cabl news network roadrunn world first consum broadband servic pathfind one first internet advertis platform presid obama appoint mr sagan presid nation secur telecommun advisori committe serv fellow american academi art scienc sinc name ernst young entrepreneur year technolog categori world econom forum name mr sagan global leader tomorrow mr sagan graduat medil school journal northwestern univers life truste also serv chairman board director propublica appoint governor charli baker chairman massachusett board elementari secondari educ slaoui ph former chairman global vaccin glaxosmithklin plc moncef slaoui ph previous serv chairman global vaccin glaxosmithklin plc gsk previou role gsk also includ chairman global research develop vaccin chairman research develop senior vice presid world-wide busi develop extern allianc dr slaoui chairman gsk pipelin invest board pib serv director gsk current serv chairman board galvani bioelectronics-ded biotech co-own gsk verili alphabet compani dr slaoui previous member advisori board agenc scienc technolog research singapor member nation institut nih advisori committe director current serv member advisori board qatar foundat dr slaoui professor immunolog univers mon belgium author scientif paper present dr slaoui earn ph molecular biolog immunolog univers libr de bruxel belgium complet postdoctor studi harvard medic school tuft univers school medicin boston comment board scientif founder ventur capitalist pharmaceut healthcar expert broad deep expertis seven director independ outperform
headquart cambridg manufactur facil
norwood kendal squar campu cambridg compris offic research
headquart well platform drug discoveri process develop clinic
develop facil cambridg facil leas leas expir
major space leas option
extend leas need norwood manufactur facil approxim
squar feet site research-grad mrna clinic suppli manufactur
accord fda current manufactur practic cgmp regul
norwood site leas option extend two ten-year term
norwood site construct second half follow
decis invest dedic in-hous manufactur facil due expect
on-going pipelin expans long lead-tim requir build manufactur
infrastructur invest million norwood facil date
facil scale cgmp lot per year expect accommod
employe norwood facil support phase ii pipelin potenti
support later stage clinic develop activ well commerci activ
facil becam oper juli
norwood site includ follow featur five current cgmp suit
manufactur drug substanc bulk drug product dedic cgmp suit steril
fill manufactur person cancer vaccin pcv manufactur critic
raw materi space packag label storag vial product
temperature-control warehous incom outgo product quality-control
laboratori pilot scale manufactur space scale-up manufactur toxicolog
suppli space manufactur research-grad mrna clean util
includ purifi water water inject gener control distribut
norwood facil design integr autom digit infrastructur
manufactur record data collect deploy autom materi
resourc manag use enterpris resourc plan softwar autom
laboratori execut system laboratori inform manag system asset
document manag system ensur complet digit integr
manufactur product test releas regulatori file integr enabl
keep strict manufactur data control facilit optim asset
resourc util schedul meet scale clinic need
manufactur current support research engin earli develop
engin eventu support demand late-stag develop
commerci engin manufactur technolog develop done advanc
suppli includ develop technolog mrna drug product
manufactur test qualiti consist suppli meet target product
profil low cycl time manufactur technolog also need support scale-up
industri product eventu commerci approv current
broad pipelin develop program signific output necessari
variou toxicolog clinic studi
believ infrastructur capac crucial advanc platform
technolog develop therapeut area discoveri effort suppli research
engin high-throughput autom custom-engin equip enabl product
multipl high-qual mrna formul construct within week order
deliveri research scientist compani strateg collabor
current capabl produc uniqu mrna sequenc per
month turnaround time week mrna sequenc final product
typic scale mrna manufactur team mg produc
lot research-grad mrna date
also contract third-parti contract manufactur organ cmo
addit manufactur capac provid suppli conting expand capabl
need
invest digit infrastructur support manufactur drug
artifici intellig cloud comput digit strategi use
consist set digit applic across multipl busi process streamlin
oper rapidli iter process record implement improv
exampl benefit better qualiti control integr autom reduc human
error scalabl evidenc pipelin growth program present five
program year-end increas speed mrna manufactur anticip
respons grow demand cost save
digit infrastructur categor six primari applic cloud enabl
busi integr internet thing autom advanc analyt artifici
intellig cloud enabl provid advantag lower cost store data
cloud save provis administr expens also provid
scalabl secur data collect busi integr involv share data
across oper segment ensur consist streamlin workflow internet
thing technolog interconnect devic enabl real-tim synchron
oper data equip provid guidanc scientist engin
gener enabl larger scale oper reliabl includ use
robot manufactur advanc analyt enabl research draw insight
large-scal data set artifici intellig enabl constant improv mrna
design algorithm base machin learn also provid critic insight
research suppli chain manufactur process base feedback loop
perform current process
drug design studio proprietari in-hous softwar assist
product mrna drug design studio contain sequenc design modul tailor
entir mrna utr code region utr also includ
constantli improv rule set contain accumul learn mrna design
drug design studio use cloud comput run variou algorithm research
develop design mrna sequenc provid flexibl capac parallel
intak design multipl mrna sequenc drug design
manufactur mrna involv proprietari interfac enabl manufactur
team track product order stage equip use manufactur
mrna integr digit interfac data traceabl mrna
order produc shipment digit track includ barcod label
sent scientist extern conduct vivo studi materi inventori
digit applic enabl track support workflow tool like consumpt
aliquot materi transfer stock alert well assign critic materi
uniqu registri identif studi design proprietari applic
captur vivo studi protocol design paramet dose amount frequenc
sampl assay enabl scientist track design pharmacolog team
track on-going studi manag demand addit electron laboratori notebook
experi manag enabl scientist streamlin document track
experi searchabl repositori notebook also integr
inventori vivo studi instrument data
advanc analyt artifici intellig enabl acceler effici
oper throughout drug discoveri develop manufactur exampl
applic drug discoveri includ use neural network protein mrna
engin involv analyz model protein sequenc use input
optim potenti sequenc predict mrna sequenc enhanc protein
express machin learn sequenc mrna use bayesian model acceler
assess sequenc data rapidli provid scientist mrna clinic
develop oper includ digit applic timelin regulatori file
plan ind-en glp toxicolog studi schedul cgmp manufactur
clinic oper manag document manag system provid real-tim
inspect readi visibl control regulatori submiss archiv
manufactur process involv digit system robot autom product
track analysi process improv exampl includ enterprise-qu
manag system manag product deviat creat prevent action
laboratori inform manag system data analysi qualiti control
computer mainten manag system equip mainten
calibr enterpris resourc plan execut system manag
inventori raw materi consumpt well integr equip
manufactur recip batch order
moderna pcv program aim design manufactur deliv drug product
includ mrna sequenc encod patient specif neoantigen
person therapi add complex overal treatment process compar
tradit medicin address complex digit autom
step process patient provid uniqu identifi use
track throughout workflow process patient ultim receiv specif
drug manufactur design mrna sequenc pcv program
involv use neural network proprietari vaccin design algorithm
select top neoantigen use determin specif amino acid
sequenc trigger desir immun respons use mont carlo
simul pcv supply/demand manag product capac ensur
bottleneck avoid stage workflow sinc drug person
revenu collabor grant estim
product revenu start anticip launch
first product base outlook could launch first three
potenti growth product remain ten estim revenu
could increas billion
estim year-end expens increas million
million sg expens increas million million
oper loss increas loss million loss million
assum fulli develop commerci compound without
addit partner strateg investor estim oper loss increas
next seven year compound-annual-growth-rate compani turn profit
revenu start meaning off-set loss estim oper incom
million scenario estim sg expens
increas averag per year next seven year
respect line industri averag percentag product sale
dilut ep expect neg turn posit
estim oper cash flow neg
neg oper cash flow expect off-set financ
activ assum strategi wherebi develop
commerci compound addit partner estim need
rais approxim billion fund program
current estim launch rsv cmv mrna-
mma pa
estim suffici cash fund develop
program estim need approxim billion
addit cash
believ success next sever year highli depend
posit clinic data fda approv launch current experiment
biggest risk product candid gain fda approv therefor
becom commerci product gain fda approv risk
includ manufactur secur favor price third parti reimburs
patient drug cost patient behavior physician adopt product maintain
patent protect structur chang healthcar market
convers estim sell price experiment product low
gain fda approv indic sooner model
market penetr rapid estim would signific
upsid estim
follow exhibit provid histor project incom statement exhibit
balanc sheet exhibit cash flow exhibit statement along product detail
experiment therapi exhibit
exhibit incom statement histor estim continu next page
inc nasdaq-syr incom statement thousand except per share vaccinesrsv vaccinespcv regen therapeuticsvegf-a secret proteinsfabri diseas intracellular product revenu relat good incom incom redeem convert prefer unit redempt stock incom avail common share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit balanc sheet histor estim continu next page
inc nasdaq-syr balanc sheet thousand except per share asset restrict refund incom account receiv account prepaid expens current cash stockhold equitycurr liabil account accru commit capit defer defer leas current current revenu leas financ long-term equiti redeem prefer stock common addit paid-in accumul comprehens accumul deficit/retain stockhold liabil compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit flow histor estim continu next page
inc nasdaq-syr statement thousand except per share data flow oper net depreci net loss fix amort discount stock-bas defer incom chang asset prepaid expens current restrict account receiv account receiv account defer accru expens defer incom defer leas cash provid oper flow invest activ proce sale market proce matur market purchas market purchas properti plant increas restrict cash provid invest flow financ activ proce issuanc restrict proce equiti proce convert distribut prefer common unit construct financ net proce share base cash provid financ increas cash cash begin end cash cash flow per cash flow per share cash cash flow per cash flow per share compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit rsv detail refer found end section end note
sale detailrsv patient populationrsv incidenceelderli rsv case year age size elderli rsv case rsv case penetrationelderli rsv case rsv case treatedelderli rsv case rsv case per cours therapi increasessal thousand elderli us rsv vaccin sale ex-u rsv vaccin sale ww rsv vaccin sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit cmv detail refer found end section end note
cmv patient populationcmv incid size to-be-moth penetrationto-be-moth treatedto-be-moth per cours therapi price increasessal thousand to-be-moth us cmv vaccin sale ex-u cmv vaccin sale thousand ww cmv vaccin sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit detail refer found end section end note
size elderli hmpv incid age infect penetrationelderli hmpv incid age infect treatedelderli hmpv incid age infect per cours therapi hmpv age infect increasessal thousand elderli hmpv age infect us hmpv vaccin sale ex-u hmpv vaccin sale thousand ww hmpv vaccin sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit pcv detail refer found end section end note
pcv patient cancer line cell lung cancer line neck line line cancer line size colorect cancer recurr line cell lung cancer recurr line neck recurr line recurr line cancer recurr line penetrationcolorect cancer recurr line cell lung cancer line neck recurr line cancer recurr treatedcolorect cancer recurr line cell lung cancer line neck recurr line cancer recurr per cours therapi cancer recurr line cell lung cancer line neck recurr line cancer recurr increasessal thousand colorect cancer recurr line cell lung cancer line neck recurr line cancer recurr us pvc sale ex-u pvc sale ww pvc sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit kra detail refer found end section end note
kra patient cell lung cancer line cancer line cancer line size non-smal cell lung cancer line cancer line cancer line penetrationnon-smal cell lung cancer line cancer cancer treatednon-smal cell lung cancer line cancer cancer per cours therapi cell lung cancer line cancer cancer thousand non-smal cell lung cancer line cancer cancer us kra sale ex-u kra sale ww kra sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit detail refer found end section end note
patient cancer neck cancer line size metastat breast cancer tripl neg neck line penetrationbreast cancer neck line treatedbreast cancer neck line per cours therapi cancer neck line increasessal thousand breast cancer neck line us sale ex-u sale thousand ww sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit detail refer found end section end note
patient cancer neck cancer line size metastat breast cancer tripl neg neck line penetrationbreast cancer neck line treatedbreast cancer neck line per cours therapi cancer neck line increasessal thousand breast cancer neck line us sale ex-u sale thousand ww sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibita vegf-a fabri diseas detail refer found end section end note
vegf-a patient failur patient size cabg procedur penetrationcabg procedur treatedcabg procedur per cours therapi failur increasessal thousand heart failur us vegf-a sale ex-u vegf-a sale thousand ww vegf-a sale compani data oppenheim co estimatesaddit inform avail upon request fabri diseas patient diseas size fabri penetrationfabri treatedfabri per cours therapi increasessal thousand fabri us fabri diseas sale ex-u fabri diseas sale thousand ww fabri diseas sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit relaxin mma detail refer found end section end note
relaxin patient failur patient size heart failur patient hospit penetrationheart failur treatedheart failur per cours therapi failur increasessal thousand heart failur us relaxin sale ex-u relaxin sale thousand ww relaxin sale compani data oppenheim co estimatesaddit inform avail upon request mma patient acidemia size methylmalon penetrationmethylmalon treatedmethylmalon per cours therapi increasessal thousand methylmalon us mma sale ex-u mma sale thousand ww mma sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit pku pa detail refer found end section end note
pku patient case pku size phenylketonuria penetrationphenylketonuria treatedphenylketonuria per cours therapi increasessal us pku sale ex-u pku sale ww pku sale compani data oppenheim co estimatesaddit inform avail upon request pa patient acidemia size propion penetrationpropion treatedpropion per cours therapi increasessal thousand propion us pa sale ex-u pa sale thousand ww pa sale compani data oppenheim co estimatesaddit inform avail upon request outperform
end note refer exhibit
incid deriv ional cancer institut nci seer incid deriv ional cancer institut nci seer data percentag expect relaps base robert et al nejm incid deriv ional cancer institut nci seer data percentag expect relaps base von der maas et al jco deriv ional cancer institut nci seer estim boland cr microsatellit instabl colorect cancer gastroenterolog neg breast cancer account breast cancer incid deriv ional cancer institut nci seer incid deriv ional cancer institut nci seer cdc rsv current lead approxim hospit among adult older year children five year old hospit due rsv accord ional institut total popul number children five year old us approxim accord feder interag forum child famili per year use synagi compar per year use checkpoint inhibitor compar ch et al women issu per year use gardasil compar censu per year use prevnar compar incid deriv ional cancer institut nci seer incid deriv ional cancer institut nci seer incid deriv ional cancer institut nci seer mutat occur nsclc brose et al reilli et al mutat occur amado et al cosmic faulkner et al neumann et al mutat occur pancreat cancer hingorani et al cancer cell per year use checkpoint inhibitor compar incid deriv ional cancer institut nci seer per year use checkpoint inhibitor compar ure per year use entresto compar report incid per year use fabrazym compar heart failur case accord du et al ure iew cardiolog du et al cardiol estim rang hospit per year use entresto compar per year use cerezym compar incid deriv ional cancer institut nci seer rang incid rate cite nord rang estim total us pku patient popul approxim per year use palynziq compar per year use cerezym compar outperform
cmv vaccin design manufactur prevent congenit
cytomegaloviru cmv infect multi-antigen vaccin combin target
antigen gb pentam specif focu immun system believ
give greater potenti produc neutral antibodi block cmv
transmiss mother fetu either directli vaccin adolesc
adult child-bear potenti femal male indirectli vaccin toddler
could spread cmv mother childcar worker
compris six mrna encod known hard-to-mak cmv antigen
proprietari lnp program current investig phase clinic trial
studi initi novemb expect complet june initi result
publish journal vaccin august dose-escal
part portion trial evalu mrna altern vaccin transplant
patient complet enrol
cmv vaccin current evalu prevent congenit
transmiss cmv infect
cmv vaccin administ subcutan inject phase studi design
administ vaccin three-dos vaccin schedul month three
dose level cmv seroneg cmv-seroposit
still experiment therapi therefor establish price
conserv estim potenti price cours therapi
annual cost gardasil howev pure oppenheim co estim base
avail price data dosag data gardasil prescript label
current evalu cmv vaccin phase studi
phase healthi adult patient
sponsor random observer-blind placebo-control dose-rang
phase studi evalu safeti immunogen cmv vaccin mrna
healthi adult patient unit state elig patient cmv-seroneg
cmv-seroposit subject receiv cmv vaccin three-dos vaccin schedul
month three dose level primari endpoint
safeti reactogen key secondari endpoint immunogen studi
design enrol patient current enrol approxim patient
present initi novemb estim primari complet date
june anticip data approxim two month patient
receiv second dose vaccin
awar patent specif file would
consist earli clinic stage develop howev identifi
patent protect platform technolog use discoveri
develop mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl
infring expir appendix
women becam pregnant two-year studi pregnanc
intend accord chuang ch weisman cs hillemei mm camacho ft dyer a-
cepawh women health issu appli rate annual number
birth per year center diseas control cdc document
estim total address market cmv vaccin women intend
becom pregnant approxim per year exhibit survey
infecti diseas physician us respond would prescrib
mrna vaccin cmv avail infecti diseas survey januari
exhibit data obtain cdc estim preval cmv incid preval base us censu
approv estim cmv vaccin enter cmv market
market penetr to-be-moth popul
conserv estim achiev market penetr set
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim cmv set
averag price per cours therapi per annual treatment base
estim price gardasil estim world-wide cmv vaccin
sale increas billion howev pure oppenheim co
estim provid strategi price exhibit
exhibit estim world-wide cmv vaccin sale grow billion
penetrationto-be-moth treatedto-be-moth per cours therapi price increasessal thousand to-be-moth us cmv vaccin sale ex-u cmv vaccin sale thousand ww cmv vaccin sale compani data oppenheim co estimatesaddit inform avail upon request outperform
prophylact vaccin respiratori syncyti viru rsv
design manufactur collabor merck includ encod membrane-
anchor version stabil prefus protein main target potenti
neutral protect antibodi current evalu phase
trial australia merck also identifi back-up mrna candid
immunogen one-fifth dose preclin model decis
advanc current program back-up program
base emerg clinic data
current evalu prevent treatment respiratori
administ singl intramuscular inject boost moderna
on-going phase studi evalu three dose level younger adult
 four dose level older adult
still experiment therapi therefor establish price
conserv estim potenti price cours therapi
annual cost synagi current standard care howev pure
oppenheim co estim base avail price data dosag data
current evalu phase trial australia vaccin
respiratori syncyti viru rsv younger older adult patient trial met
object demonstr suffici safeti toler immunogen profil
day partner merck initi plan phase ii trial
phase patient respiratori syncyti viru rsv australia
collabor merck sponsor random partial double-blind
placebo-control dose-escal first-in-human studi evalu safeti toler
immunogen healthi adult subject phase studi fulli enrol
patient australia
studi evalu three dose level younger adult
four dose level older adult subject
given singl intramuscular inject studi conduct two part
 part evalu younger subject age year part evalu
older subject age year subject dose key
endpoint studi includ safeti toler versu placebo
evalu immunogen measur serum neutral antibodi
titer rsv
studi met object demonstr suffici safeti toler
immunogen profil april major data
day post-vaccin younger subject arm
placebo arm placebo arm placebo older
subject arm placebo arm placebo arm
placebo continu collect safeti toler immunogen data
day studi consist studi protocol
decis advanc current program phase ii merck
base interim data april back-up program base
emerg clinic data
awar patent specif file would
consist earli clinic stage develop howev identifi patent
protect platform technolog use discoveri develop
mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl infring expir
appendix
base annual incid rate children five year old hospit
due rsv accord nation institut total popul number
children five year old us approxim accord
feder interag forum child famili statist estim total
address market approxim us per year
respiratori syncyti viru rsv infect one common caus
childhood ill accord center diseas control cdc rsv lead
annual outbreak respiratori ill age group region unit
state rsv usual circul fall winter spring vari season
time region symptom usual includ runni nose decreas appetit cough
sneez fever wheez symptom usual appear stage
young infant rsv symptom may irrit decreas
activ breath difficulti rsv also caus sever infect
bronchiol inflamm small airway lung pneumonia infect
lung common caus bronchiol pneumonia children
younger one year age almost children rsv infect
second birthday peopl infect rsv usual show symptom within four six day
infect accord cdc rsv current lead approxim
outpati visit among children five year old hospit among
children younger five year old hospit among adult older
year estim death among adult older year
exhibit survey infecti diseas physician us respond
would prescrib mrna vaccin rsv avail infecti diseas survey
exhibit data obtain nihi estim preval rsv incid preval base us censu nih
approv estim rsv enter pediatr
adult rsv market market penetr conserv
estim achiev market penetr set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
respiratori syncyti viru patient populationelderli rsv case year age size elderli rsv case rsv case syncyti viru penetrationelderli rsv case rsv case treatedelderli rsv case rsv case therapeut
sale estim base market penetr estim rsv vaccin
averag price per therapi annual base price
synagi estim world-wide rsv sale increas
billion howev pure oppenheim co estim
provid strategi price exhibit
exhibit estim world-wide rsv sale grow billion
respiratori syncyti viru treatedelderli rsv case rsv case per cours therapi increasessal thousand elderli us rsv vaccin sale ex-u rsv vaccin sale ww rsv vaccin sale compani data oppenheim co estimatesaddit inform avail upon request outperform
combin prophylact vaccin hmpv design
manufactur consist two distinct mrna sequenc encod membran
protein co-formul lipid nanoparticl lnp deliveri system
prevent treat infant toddler hmpv may caus respiratori tract
infect often lead hospit current investig
phase trial healthi adult subject us decemb estim
primari complet date juli pend result plan evalu mrna-
seroposit toddler
current evalu prevent treatment human
metapneumoviru hmpv human parainfluenza viru
administ intramuscular inject on-going phase studi
evalu four dose level day month
still experiment therapi therefor establish price
estim potenti price base current price prevnar
cost approxim per year standard cours treatment
oppenheim co estim base avail price data dosag data
current evalu phase ib trial us vaccin
hmpv healthi adult
phase ib patient healthi adult
sponsor random observer-blind placebo-control dose-rang
studi evalu safeti reactogen immunogen
administ healthi adult phase studi fulli enrol subject
juli dose-escal phase studi assess four dose
 administ intramuscularli day month
month immun random placebo primari
endpoint frequenc solicit reactogen event day follow dose
administr frequenc unsolicit advers event follow day follow
dose administr frequenc seriou advers event one year follow last
dose administr base unblind evalu safeti data three highest
dose level evalu dose select phase
studi initi decemb estim primari complet date juli
note enrol complet patient plan
evalu seroposit toddler pend success result phase
trial anticip data coupl month patient receiv
preclin studi evalu multipl combin mrna vaccin
encod full-length protein hmpv virus mice spragu dawley rat
cotton rat african green monkey follow intramuscular im
inject observ studi demonstr mrna encod
protein virus induc robust neutral antibodi titer speci
awar patent specif file would
consist earli clinic stage develop howev identifi
patent protect platform technolog use discoveri
develop mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl
infring expir appendix
nation institut health cite annual incid rate
hospit due hmpv respect children five year old
us given total popul us children five year old approxim
accord feder interag forum child famili statist
estim total respect popul hmpv patient
per year total address market approxim
exhibit data obtain nihi estim preval hmpv incid preval base us
censu nih incid
metapneumoviru hmpv rna viru determin frequent caus
upper lower respiratori tract infect hmpv primarili affect young children
also infect adult elderli immunocompromis individu clinic sign infect
rang mild upper respiratori tract infect life-threaten sever bronchiol
pneumonia
parainfluenza viru also rna viru caus respiratori tract
infect children four piv type frequent result
infect lead seriou lower respiratori tract infect major
either hmpv hospit occur children two year old
approv estim enter pediatr hmpv
market market penetr conserv estim
achiev market penetr set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim hmpv
vaccin averag estim price per therapi annual
base current price prevnar expect modest price increas
estim world-wide sale increas billion howev
pure oppenheim co estim provid strategi
price exhibit
human metapneumoviru hmpv parainfluenza viru incid market size elderli hmpv incid age infect metapneumoviru hmpv parainfluenza viru penetrationelderli hmpv incid age infect
exhibit estim world-wide sale grow billion
human metapneumoviru hmpv parainfluenza viru treatedelderli hmpv incid age infect per cours therapi hmpv age infect increasessal thousand elderli hmpv age infect us hmpv vaccin sale ex-u hmpv vaccin sale thousand ww hmpv vaccin sale compani data oppenheim co estimatesaddit inform avail upon request outperform
person neoantigen vaccin design
manufactur includ immunogen antigen select present patient
tumor co-administ keytruda pembrolizumab
develop collabor merck administ monotherapi
patient advanc metastat cancer differ
neoantigen select process candid current investig phase
trial us
current evalu combin keytruda
pembrolizumab monotherapi respect treatment prevent
administ intramuscular inject
merck on-going phase trial administ first day
cycl maximum nine dose level mg mg mg mg
still experiment therapi therefor establish price
conserv estim potenti price cours therapi base
current price checkpoint inhibitor howev pure oppenheim co
estim provid strategi price
current evalu collabor merck phase trial
previous conduct preclin studi evalu phase
studi conduct nation cancer institut nci understand nci
run meticul approach studi high prioriti nci
phase monotherapi subject resect solid tumor
combin keytruda patient unresect solid tumor keynote-
sponsor open-label multicent phase studi collabor
merck phase studi assess safeti toler immunogen
monotherapi patient resect solid tumor combin
keytruda pembrolizumab patient unresect solid tumor
administ intramuscular inject first day
cycl maximum nine dose administ monotherapi
part combin pembrolizumab part us
dose level mg mg mg mg explor part part
 primari endpoint safeti toler measur part dose
escal day safeti toler part baselin day
last dose well part baselin day
last pembrolizumab dose studi design enrol patient initi august
estim primari complet date septemb
base interim data june part first two dose level
mg patient mg patient monotherapi well
toler dose-limit toxic immunogen
observ first two dose cohort absenc cpi
plan initi random phase ii studi
phase i/ii patient metastat melanoma epitheli cancer
partner nation cancer institut nci sponsor phase i/ii trial
evalu safeti immunogen pcv treatment patient
metastat melanoma colon gastrointestin genitourinari hepatocellular cancer
studi two experiment arm arm phase dose-escal cohort
arm phase ii maximum toler dose cohort establish arm
arm patient may receiv mrna-bas vaccin intramuscularli two-week
interv four cycl patient may vaccin second final cours
treatment use vaccin dose second cours may start approxim
four week plu minu two week last vaccin dose
primari endpoint object tumor regress aggreg treatment-rel
advers event includ frequenc sever secondari endpoint quantiti
qualiti circul antigen-specif t-cell studi design enrol patient
initi may estim primari complet date may
awar patent specif file
would consist earli clinic stage develop howev
identifi patent protect platform technolog use
discoveri develop mrna therapeut forty-four patent
expir date addit patent in-licens avoid
possibl infring expir appendix
base pcv current clinic develop program believ address
market therapi patient colorect cancer non-smal cell lung cancer
nsclc head neck cancer melanoma bladder cancer base data
nation cancer institut nci front-lin second-lin nsclc current affect
patient respect unit state second-lin
melanoma affect patient bladder cancer affect
patient exhibit incid preval estim deriv
appli seer annual estim growth rate type cancer
exhibit data obtain nation cancer institut nci surveil epidemiolog end result seer program databas
estim preval cancer incid preval base us censu nci incid
colorect cancer cancer larg bowel colon rectum anal
canal tumor form colon rectum classifi colorect tumor
colorect cancer stage accord three variabl size locat
primari tumor metastasi lymph node metastasi organ tissu
accord american cancer societi incid colorect cancer
unit state colorect cancer highli treatabl detect earli
stage diseas treatment paradigm refer standard data treatment
set outlin appendix
non-smal cell lung cancer type epitheli lung cancer small cell lung
cancer common subtyp nsclc squamou cell carcinoma larg cell
carcinoma adenocarcinoma although nsclc frequent associ histori
cigarett smoke adenocarcinoma may also occur never smoker front-lin
therapi combin target therapi immun therapi surgeri and/or
chemotherapi activ genom alter either gene amplif
gain-of-funct mutat estim occur approxim patient
often mutual exclus known driver mutat treatment
pcv patient cancer line cell lung cancer line neck line line cancer line size colorect cancer recurr line cell lung cancer recurr line neck recurr line recurr line cancer recurr line therapeut
paradigm refer standard data treatment set outlin
head neck cancer known collect typic begin squamou
cell line mucos surfac insid head neck includ mouth nose
throat head neck cancer also begin salivari gland salivari
gland cancer rel uncommon cancer head neck
categor area head neck begin area includ
oral caviti pharynx larynx paranas sinus nasal caviti salivari gland
treatment paradigm set platinum-bas chemotherapi erbitux avastin
front-lin checkpoint inhibitor second-lin set still larg
unmet need set
melanoma malign tumor melanocyt cell make pigment melanin
melanoma develop anywher skin like start trunk
leg stage classif melanoma base follow variabl size
tumor level invas whether tumor spread lymph node
distant site treatment paradigm refer standard data treatment
set outlin appendix
bladder cancer divid three type transit cell carcinoma squamou
cell carcinoma adenocarcinoma tumor either papillari tumor
mean wart-lik lesion attach stalk non-papillari tumor non-
papillari tumor much less common invas poorer
prognosi transit cell compris innermost tissu bladder cancer
origin account bladder cancer treatment paradigm
refer standard data treatment set outlin appendix
approv estim pcv enter recurr second-lin
colorect cancer second-lin nsclc head neck cancer melanoma bladder
cancer market market penetr conserv estim
achiev market penetr set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
pcv penetrationcolorect cancer recurr line cell lung cancer line neck recurr line cancer recurr outperform
sale estim base market penetr estim colorect
cancer nsclc head neck cancer melanoma bladder cancer set
averag price per cours therapi per month base current
price checkpoint inhibitor estim world-wide pcv sale increas
billion howev pure oppenheim co estim
provid strategi price exhibit
exhibit estim world-wide pcv sale grow billion
pcv treatedcolorect cancer recurr line cell lung cancer line neck recurr line cancer recurr per cours therapi cancer recurr line cell lung cancer line neck recurr line cancer recurr increasessal thousand colorect cancer recurr line cell lung cancer line neck recurr line cancer recurr us pvc sale ex-u pvc sale ww pvc sale compani data oppenheim co estimatesaddit inform avail upon request
kra vaccin prevent treatment solid tumor cancer
kra frequent mutat oncogen epitheli cancer includ lung colorect
pancreat cancer consist mrna encod
concatem sequenc encod four common kra mutat
mrna encod constitu activ version sting immun stimul
develop combin checkpoint inhibitor moderna
develop partner merck control clinic develop merck
current plan conduct phase studi
current develop treatment prevent kras-mut
epitheli cancer includ lung pancreat cancer
administ intramuscular inject co-administ
checkpoint inhibitor merck plan dose-escal confirmatori phase trial
administ monotherapi combin merck
keytruda pembrolizumab cycl mrna dose level mg mg
mg mg
observ mrna encod kra mutat produc cell
present transgen mice specif human class allel observ
mrna-encod constitu activ sting function innat immune-stimul
activ interferon- product human cell line murin vitro
vivo model
transgen mous model express human one hla type known
express mutant kra studi transgen mice vaccin either
concatem four mutant kra neoantigen plu mrna encod sting
mrna formul lnp deliv intramuscularli day day t-
cell respons measur day re-stimul splenocyt either
medium wild-typ mutant kra peptid panel panel
report robust specif antigen specif cell respons
detect splenocyt re-stimul peptid
still experiment therapi therefor establish price
conserv estim potenti price cours therapi
per year base current price checkpoint inhibitor howev pure
oppenheim co estim provid strategi price
develop partner merck lead clinic develop
plan initi phase studi previous file ind
merck plan conduct open-label multi-cent dose-escal dose-expans
phase studi evalu safeti toler administ
intramuscular inject monotherapi combin keytruda
pembrolizumab origin file ind transfer merck mrk-
administ cycl
two part trial part dose-escal confirm part
cohort expans part design determin recommend dose phase ii
trial consist two arm respect test monotherapi
combin arm patient complet one cycl dose level
clear safeti enrol subsequ dose level open
simultan enrol arm begin dose level arm complet
one cycl clear safeti arm enrol patient may receiv nine
dose everi three week arm enrol patient may receiv nine
dose mrna dose level test mg mg mg mg part
enrol patient kra mutat
part ten particip advanc three investig arm arm
enrol patient and/or posit kra
mutat investig arm enrol patient advanc
metastat nsclc investig arm enrol patient advanc
metastat investig arm enrol patient advanc metastat
awar patent specif file would
consist preclin stage develop howev identifi patent
protect platform technolog use discoveri develop
mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl infring
expir appendix
base rang incid rate kra mutat non-smal cell lung cancer
nsclc cite brose et al reilli et al believ
total kras-mut nsclc popul approxim patient exhibit
base rang incid rate kra mutat colorect cancer
cite amado et al cosmic faulkner et al neumann et al
believ total kras-mut popul approxim
patient exhibit
base rang incid rate kra mutat pancreat cancer
cite hingorani et al cancer cell believ total kras-mut
pancreat cancer popul approxim patient exhibit
exhibit data obtain peer-review sourc estim preval kras-mut cancer incid
preval base us censu peer-review sourc
non-smal cell lung cancer type epitheli lung cancer small cell lung
cancer common subtyp nsclc squamou cell carcinoma larg cell
carcinoma adenocarcinoma although nsclc frequent associ histori
cigarett smoke adenocarcinoma may also occur never smoker front-lin
therapi combin target therapi immun therapi surgeri and/or
chemotherapi activ genom alter either gene amplif
gain-of-funct mutat estim occur approxim patient
often mutual exclus known driver mutat treatment paradigm
refer standard data treatment set outlin appendix
colorect cancer cancer larg bowel colon rectum anal
canal tumor form colon rectum classifi colorect tumor
colorect cancer stage accord three variabl size locat
primari tumor metastasi lymph node metastasi organ tissu
accord american cancer societi incid colorect cancer
unit state colorect cancer highli treatabl detect earli
stage diseas treatment paradigm refer standard data treatment
set outlin appendix
pancreat cancer malign pancrea gland make insulin
hormon help bodi use store energi come food exampl
insulin help control amount sugar blood pancrea also make
enzym help digest food pancrea releas enzym system
duct lead common bile duct common bile duct empti duodenum
first section small intestin accord nci pancreat cancer
begin duct refer bile duct cancer cancer pancrea
metastas area outsid pancrea lymph node liver lung
peritoneum tissu line abdomin caviti accord american cancer
societi annual incid pancreat cancer roughli death rate
due extrem poor prognosi diseas patient stage
pancreat cancer elig treatment experiment chemotherapi agent
clinic trial set treatment paradigm refer standard data treatment
set outlin appendix
approv estim kra vaccin enter second-lin
nsclc pancreat cancer market market penetr
conserv estim achiev market penetr set
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim nsclc
pancreat cancer set averag price per cours therapi
per month base current price checkpoint inhibitor estim
world-wide kra vaccin sale increas billion
howev pure oppenheim co estim provid
strategi price exhibit
exhibit estim world-wide kra vaccin sale grow billion
kra treatednon-smal cell lung cancer line cancer cancer per cours therapi cell lung cancer line cancer cancer thousand non-smal cell lung cancer line cancer cancer us kra sale ex-u kra sale ww kra sale compani data oppenheim co estimatesaddit inform avail upon request outperform
mrna encapsul proprietari lipid
nanoparticl lnp deliv via intratumor inject treatment advanc
metastat solid tumor combin checkpoint inhibitor mrna sequenc
engin enhanc protein product design decreas
amount protein made hepatocyt better toler develop
collabor astrazeneca current plan phase clinic
trial combin checkpoint inhibitor previous
conduct preclin trial observ greater complet respons rate
mice dose antibodi
current plan evalu adult patient immunolog cold-
medi administ intratumor inject plan phase trial design
dose monotherapi combin checkpoint inhibitor
medi still experiment therapi therefor establish price
conserv estim potenti price cours therapi base
current price checkpoint inhibitor howev pure oppenheim co
estim provid strategi price
preclin studi observ treatment transform tumor
microenviron notabl activ natur killer dendrit cell
increas cytotox lymphocyt checkpoint inhibitor refractori mous model
singl dose mrna yield approxim complet respons rate
mrna monotherapi synergist activ system administ anti-
antibodi demonstr complet respons rate greater test
articl administ day mrna treatment day
antibodi treatment antibodi treatment administ mg/kg
mice per group studi synergi local administ mrna
system treatment also observ distal tumor directli
administ mrna
collabor astrazenca sponsor lead clinic
develop conduct preclin studi mice result
data support ind/ca file expect lower start dose medi-
clinic trial compar intratumor program
dose monotherapi combin checkpoint inhibitor plan
phase trial note glp toxicolog studi complet
awar patent specif file would
consist preclin stage develop howev identifi patent
protect platform technolog use discoveri develop
mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl infring
expir appendix
base medi current clinic develop program believ
address market therapi patient metastat breast cancer tripl
neg mtnbc head neck cancer melanoma base data
nation cancer institut nci mtnbc current affect patient
us head neck cancer current affect patient melanoma
current affect patient us exhibit incid
preval estim deriv appli seer annual estim growth rate
type cancer
exhibit data obtain peer-review sourc estim preval cancer incid preval base
us censu peer-review sourc
breast cancer present sever differ type common ductal
carcinoma begin line duct anoth type lobular carcinoma aris
lobul accord american cancer societi incid breast cancer
unit state accord nci breast cancer stage rang
stage stage iv depend size tumor invas breast cancer
divid molecular subtyp base hormon receptor tumor express
estrogen receptor progesteron receptor refer hormon receptor hr
posit tumor overexpress protein refer
treatment paradigm refer standard data treatment
set outlin appendix
head neck cancer known collect typic begin squamou
cell line mucos surfac insid head neck includ mouth nose
throat head neck cancer also begin salivari gland salivari
gland cancer rel uncommon cancer head neck
categor area head neck begin area includ
oral caviti pharynx larynx paranas sinus nasal caviti salivari gland
melanoma malign tumor melanocyt cell make pigment melanin
melanoma develop anywher skin like start trunk
leg stage classif melanoma base follow variabl size
tumor level invas whether tumor spread lymph node
distant site treatment paradigm refer standard data treatment
set outlin appendix
approv estim enter mtnbc head neck cancer
second-lin melanoma market market penetr
conserv estim achiev market penetr set
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim mtnbc head
neck cancer second-lin melanoma set averag price per cours
therapi per month base current price checkpoint inhibitor
estim world-wide sale increas billion howev
pure oppenheim co estim provid strategi
price exhibit
exhibit estim world-wide sale grow billion
treatedbreast cancer neck line per cours therapi cancer neck line increasessal thousand breast cancer neck line us sale ex-u sale thousand ww sale compani data oppenheim co estimatesaddit inform avail upon request outperform
t-cell co-stimul consist mrna code ligand
formul proprietari lipid nanoparticl lnp deliveri mechan
design manufactur decreas amount protein could
made hepatocyt incorpor microrna bind site potenti
reduc off-target effect result better toler specif anti-tumor immun
respons expect induc via prolifer migrat t-cell clone
specif cancer may also result system anti-tumor respons
administ intratumor inject current sponsor phase trial
us pend addit data may choos
clinic develop
current evalu adult patient advanc relapsed/
refractori solid tumor malign lymphoma
administ intratumor inject on-going phase trial
administ day day cycl maximum
six cycl dose level test mg mg mg mg
current evalu phase dose-escal trial
clinic develop
phase dose-escal studi intratumor inject patient
advanc malign
sponsor phase open-label multicent dose-escal studi design
determin safeti toler repeat intratumor inject
patient advanc relapsed/refractori r/r solid tumor malign particularli
ovarian cancer lymphoma studi includ two dose period dose-escal
period approxim patient follow expans period addit
patient maximum toler dose /recommend dose expans rde
determin dose-escal period subset patient enrol one
follow three biopsi cohort baselin biopsi abscop distal untreat tumor
second biopsi within cycl day distal tumor baselin biopsi primari
tumor treat second biopsi hour post-dos cycl day inject
tumor baselin biopsi primari tumor treat second biopsi hour
post-dos cycl day inject tumor primari endpoint safeti toler
secondari endpoint percentag subject antibodi maximum
observ serum concentr area serum concentration-tim
curv overal respons rate durat respons progression-fre surviv
studi design enrol patient initi august estim
primari complet date juli note patient alreadi eight
cycl without experienc toxic
juli patient dose phase trial
interim data suggest subset patient protein level
administr higher pre-dos patient observ
rapid onset grade grade transient revers injection-rel reaction
resolv receptor blockad corticosteroid and/or
report three susar one grade sae describ
second susar report skin ulcer due tissu defect regress
inject tumor third susar report grade system immun reaction
patient kept overnight hospit observ
publish data studi present novemb
societi immunotherapi cancer investig highlight block co-
inhibitori checkpoint becom standard treatment divers solid hematolog
malign howev checkpoint inhibitor alon suffici induc robust
durabl tumor regress major patient gener optim anti-tumor t-cell
respons requir t-cell receptor activ co-stimul may occur via
ligat tumor necrosi factor tnf receptor famili member includ
receptor cluster differenti express activ
immun effector cell t-cell natur killer nk cell ligand
homo-trimer transmembran protein normal express antigen present cell
upon immun stimul bind presenc recogn
antigen promot expans t-cell enhanc memori
respons inhibit regulatori t-cell induct express tumor
cell cell present tumor antigen may trigger specif cell-medi
immun respons system anti-tumor effect novel mrna-bas
therapi encod human durabl tumor regress observ
preclin model intratumor administ mrna encod complet
investig conclud toler dose level studi
cutoff date dose-limit toxic dlt report major
grade clear increas protein express
observ tumor stromal region three five post-treat biopsi
collect inject tumor possibl dose respons relationship
evalu continu assess addit dose level on-going analys
addit pair biopsi use wider set mqif assay well rna
sequenc allow character baselin tumor immun
microenviron patient well pharmacodynam effect
clinic observ regress inject local region tumor made
two patient ovarian carcinoma may warrant explor futur studi
anticip patient studi eventu transfer on-going phase
studi
awar patent specif file would
consist earli clinic stage develop howev identifi
patent protect platform technolog use discoveri
develop mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl
infring expir appendix
t-cell co-stimul consist three mrna encod human
interleukin interleukin gamma formul moderna
proprietari lipid nanoparticl lnp deliveri system administ intratumor
membran protein secret cytokin ignit
and/or transform inflammatori respons within tumor microenviron three
mrna design decreas amount protein could made hepatocyt
incorpor microrna bind site potenti reduc off-target effect
result better toler
current plan evalu adult patient solid tumor
administ intratumor inject plan phase trial
administ monotherapi combin checkpoint
still experiment therapi establish price
conserv estim potenti price cours therapi base
current price checkpoint inhibitor howev pure oppenheim co
estim provid strategi price
file ind plan phase trial us israel test safeti
toler monotherapi combin checkpoint inhibitor
previous conduct preclin studi observ greater
complet respons rate mice
phase dose-escal studi patient solid tumor lymphoma
file ind phase open-label multicent studi intratumor
inject monotherapi combin checkpoint inhibitor
studi three treatment arm arm test monotherapi
arm test combin durvalumab inhibitor arm
test combin tremlimumab inhibitor studi
consist three dose-escal three dose-confirm part follow dose-
expans arm first two dose level arm clear
safeti dose escal arm start first dose level arm clear
safeti dose escal arm start stagger
first second patient studi arm dose studi
mg arm administ everi two week
three dose arm combin durvalumab
administ everi four week three cycl arm combin mrna-
tremelimumab administ everi four week three cycl biopsi
blood sampl collect pre- post-treat mrna dose
escal dose expans assess protein express chang tumor
immun landscap object studi safeti toler
administ monotherapi combin checkpoint inhibitor
defin maximum toler dose recommend dose expans
intratumor inject assess anti-tumor activ protein express
tumor pharmacokinet exploratori endpoint includ assess
immunolog respons studi design enrol particip
anticip begin novemb estim primari complet date
preclin studi observ combin local therapi
mrna achiev complet respons rate two
syngen mous model cancer one normal rel respons
complet refractori system checkpoint inhibitor treatment triple-
combin therapi better result individu doublet mrna combin
note one studi mice carri bilater tumor receiv
total mrna inject right flank tumor mrna administ
doublet triplet combin surviv event trigger
anim surpass predetermin tumor burden endpoint
tumor combin twenti mice includ cohort depict
complet respond measur diseas either tumor site
treatment group respect
day post cancer cell implant also found singl dose
mrna abl induc complet diseas control treat
distal site abscop effect
awar patent specif file would
consist earli clinic stage develop howev identifi
patent protect platform technolog use discoveri
develop mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl
infring expir appendix
base current clinic develop program believ
address market therapi patient metastat breast cancer tripl
neg mtnbc head neck cancer melanoma base data
nation cancer institut nci mtnbc current affect patient
us head neck cancer current affect patient
melanoma current affect patient us exhibit
incid preval estim base appli seer annual estim
growth rate type cancer
exhibit data obtain nation cancer institut nci surveil epidemiolog end result seer program databas
estim preval cancer incid preval base us censu nci incid
breast cancer present sever differ type common ductal
carcinoma begin line duct anoth type lobular carcinoma aris
lobul accord american cancer societi incid breast cancer
unit state accord nci breast cancer stage rang
stage stage iv depend size tumor invas breast cancer
divid molecular subtyp base hormon receptor tumor express
estrogen receptor progesteron receptor refer hormon receptor hr
posit tumor overexpress protein refer
posit treatment paradigm refer standard data treatment set
outlin appendix
head neck cancer known collect typic begin squamou
cell line mucos surfac insid head neck includ mouth nose
throat head neck cancer also begin salivari gland salivari
gland cancer rel uncommon cancer head neck
categor area head neck begin area includ
oral caviti pharynx larynx paranas sinus nasal caviti salivari gland
treatment paradigm set platinum-bas chemotherapi erbitux avastin
front-lin checkpoint inhibitor second-lin set still larg
unmet need set
melanoma malign tumor melanocyt cell make pigment melanin
melanoma develop anywher skin like start trunk
leg stage classif melanoma base follow variabl size
tumor level invas whether tumor spread lymph node
distant site treatment paradigm refer standard data treatment
set outlin appendix
approv estim enter mtnbc head neck
cancer second-lin melanoma market market penetr
conserv estim achiev market penetr set
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim mtnbc head
neck cancer second-lin melanoma set averag price per cours
therapi per month base current price checkpoint inhibitor
estim world-wide sale increas billion
howev pure oppenheim co estim provid
strategi price exhibit
exhibit estim world-wide sale grow billion
treatedbreast cancer neck line per cours therapi cancer neck line increasessal thousand breast cancer neck line us sale ex-u sale thousand ww sale compani data oppenheim co estimatesaddit inform avail upon request outperform
potent angiogen factor promot growth blood vessel
design manufactur collabor astrazeneca treat ischem heart
failur mrna program salin formul without lipid nanoparticl
lnp expect act local current evalu phase iia
trial design primarili test safeti toler epicardi inject patient
undergo coronari arteri bypass graft cabg surgeri trial initi februari
estim primari complet date august
previous test phase trial type ii diabet patient demonstr dose-
depend protein product pharmacolog effect chang local blood flow
toler dose level
vegf-a current evalu patient undergo cabg surgeri
administ subcutan inject mrna encod vascular
endotheli growth factor vegf-a directli heart muscl promot cardiac
tissu revascular recoveri cardiac function given inject per
patient singl occas phase ii studi test mg mg dose per
patient vegf-a
vegf-a still experiment therapi therefor establish price
estim potenti price vegf-a could base current price entresto
cost approxim per year standard cours treatment
oppenheim co estim base avail price data dosag data
current evalu vegf-a phase ii studi europ previous
complet phase a/b trial europ
phase ii cabg patient
astrazeneca sponsor random double-blind placebo-control sequenti
design multicent studi evalu vegf-a adult patient moder impair
systol function undergo cabg surgeri elig patient receiv dose either mg
mg vegf-a form inject singl occas primari
outcom measur safeti toler includ seriou advers event advers
event electrocardiogram result exceed ich refer rang measur
nine month studi design enrol patient intent smaller
phase trial provid initi safeti data cabg patient understand
current patient enrol trial studi take place finland
sweden expand netherland initi februari
estim primari complet date august anticip data like
publish month
phase type diabet mellitu male patient
astrazeneca sponsor phase first time human fih random single-blind
placebo-control sad studi male patient type ii diabet perform
singl studi center studi consist two part male patient
age year part assess safeti toler sad intraderm
id inject modifi vegf-a rna part evalu
pharmacodynam effect id inject forearm skin part patient
studi week part patient studi week primari outcom
measur safeti toler includ advers event vital sign
electrocardiogram hematolog clinic chemistri urinalysi studi enrol
patient part part studi take place germani
initi decemb primari complet date august
result vegf-a protein post inject mrna produc high level
set expect threshold administr demonstr dose-
depend protein product pharmacolog effect chang local blood flow
diabet patient toler mrna inject intraderm demonstr
dose level causal treatment-rel advers event injection-sit
reaction occur particip receiv vegf-a mrna across part
studi design advers event injection-sit reaction mild intens
death seriou advers event advers event lead discontinu occur
awar patent specif file would
consist earli clinic stage develop howev identifi patent
protect platform technolog use discoveri develop
mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl infring expir
appendix
base data taimeh natur review cardiolog center medicar
servic organ econom cooper develop
oecd europ estim address market us europ
patient undergo cabg procedur rang approxim
per year exhibit incid preval estim
cabg procedur deriv appli annual estim growth rate
exhibit data obtain taimeh natur review cardiolog oecd europ estim preval
cabg procedur incid preval base us censu rang incid literatur
ischem heart failur ischem cardiomyopathi ic condit heart
muscl weaken result heart attack coronari arteri diseas coronari
arteri diseas cad arteri suppli blood heart muscl becom
narrow keep necessari blood reach portion heart muscl
caus damag patient develop ic left ventricl heart like becom
enlarg dilat weaken inhibit heart abil properli pump blood
lead heart failur possibl earli stage heart diseas
symptom blood flow becom impair due coronari arteri diseas patient
experi extrem fatigu short breath dizzi faint chest pain angina
edema swell abdomen cough congest difficulti sleep weight gain
ic typic caus heart attack coronari arteri diseas risk factor
condit includ famili histori coronari heart diseas high blood pressur also
known hypertens high cholesterol obes diabet mellitu end-stag kidney
diseas amyloidosi condit abnorm protein build tissu
organ includ blood vessel sedentari lifestyl histori smoke tobacco
alcohol drug abus current treatment includ lifestyl chang medic surgeri
procedur cad primari caus ic result death
unit state accord nih nation heart lung blood institut
million death global accord vo et al global region nation incid
preval year live disabl diseas injuri
systemat analysi global burden diseas studi lancet
heart diseas lead caus death unit state account
approxim one everi four death coronari arteri diseas cad primari
caus ischem heart failur affect arteri provid blood suppli cardiac
muscl current treatment includ revascular coronari arteri reliev
symptom improv cardiac function therapi reduc blood pressur
potenti help elimin excess water congest tissu beta-block
blocker diuret howev adult human unabl regener myocardium
approv estim vegf-a enter cabg procedur market
market penetr conserv estim achiev market
penetr set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim patient
undergo cabg procedur averag price per cours therapi per
year use entresto compar estim world-wide vegf-a sale
increas billion howev pure oppenheim co estim
provid strategi price exhibit
exhibit estim world-wide vegf-a sale grow billion
penetrationcabg procedur treatedcabg procedur per cours therapi failur increasessal thousand heart failur us vegf-a sale ex-u vegf-a sale ww vegf-a sale compani data oppenheim co estimatesaddit inform avail upon request outperform
therapi treatment fabri diseas design
manufactur contain mrna encod human -gal encapsul lipid
nanoparticl lnp mrna sequenc optim protein express
secret administ intraven encod enzymat activ -gal
protein restor defici defect enzym fabri diseas
current investig preclin studi vitro vivo data
mous model evalu reduct period also
evalu plasma -gal non-human primat nhp
current evalu treatment fabri diseas
administ subcutan inject preclin studi mice
administ singl dose result observ
week preclin studi nhp dose mg/kg administ everi
week four total dose
still experiment therapi therefor establish price
estim potenti price base current price fabrazym
current standard care cost approxim per year standard
cours treatment oppenheim co estim base data
fabrazym prescrib label
conduct preclin studi evalu plan
conduct open-label phase i/ii clinic trial multipl ascend dose evalu
safeti efficaci patient
conduct sever vitro vivo pharmacolog studi demonstr
nonclin proof-of-concept -gal therapi accord administr
lnp formul -gal mrna fabri mous model result signific
durabl reduct globotriaosylsphingosin tissu serum week
follow singl dose studi three fabri gla homozyg mutant
/- mice per group data normal control sequenc group specif
time point non-human primat nhp plasma -gal evalu follow iv
administr mg/kg everi week four dose four
anim per group data indic consist circul enzym circul
follow repeat administr current conduct glp toxicolog
studi anticip ind could file within approxim six
month initi toxicolog studi
awar patent specif file would
consist preclin stage develop howev identifi
patent protect platform technolog use discoveri
develop mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl
infring expir appendix
estim total patient popul approxim per
year us estim base statist cite nation fabri
diseas foundat exhibit incid preval estim
fabri diseas deriv appli annual estim growth rate popul
exhibit data obtain nih fabri foundat estim preval fabri incid preval
base us censu nih incid
fabri diseas progress multi-organ x-link lysosom storag disord
annual incid approxim one peopl affect individu
defici -gal result reduc complet inabl metabol
glycosphingolipid lysosom thu patient accumul glycosphingolipid
within lysosom ultim result cellular tissu dysfunct
fabri patient multipl organ impact includ vasculatur kidney heart
gastrointestin neurolog system sever diseas relat
amount residu enzym activ patient cell classic fabri patient
affect individu gener retain normal enzym activ diagnosi
fabri diseas gener occur childhood patient diagnos later
life usual patient present stroke renal complic
approv estim enter fabri diseas market
market penetr conserv estim achiev market
penetr set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim fabri diseas
set averag price per cours therapi per month use
fabrazym compar estim world-wide sale increas
million howev pure oppenheim co estim
provid strategi price exhibit
exhibit estim world-wide sale grow million
penetrationfabri treatedfabri per cours therapi increasessal thousand fabri us fabri diseas sale ex-u fabri diseas sale ww fabri diseas sale compani data oppenheim co estimatesaddit inform avail upon request
mrna encod human relaxin protein design engin
extend half-lif treatment acut heart failur intend iv-
preclin studi prolong durat relaxin protein product observ
rodent non-human primat nhp collabor astrazeneca may
current develop treatment heart failur
administ subcutan inject intend repeat dose
still experiment therapi therefor establish price
estim potenti price could base current price entresto
cost approxim per year standard cours treatment
oppenheim co estim base avail price data dosag data
conduct preclin studi rodent non-human
primat nhp observ relaxin mrna give rise long-last system
function protein follow intraven dose lipid nanoparticl lnp
prolong durat relaxin protein product observ rodent nhp
exposur fusion protein made mrna consider extend
exposur ten day current conduct glp toxicolog studi
base time anticip ind file within approxim six
month initi toxicolog studi
note astrazeneca may conduct phase trial
awar patent specif file would
consist preclin stage develop howev identifi patent
protect platform technolog use discoveri develop
mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl infring expir
appendix
base data du et al natur review cardiolog es cardio
estim address market us europ number patient
year old hospit due heart failur rang approxim
per year exhibit incid preval
estim heart failur deriv appli annual estim growth rate
peer review sourc survey cardiologist us respond
would relaxin acut heart failur avail respond would use
chronic heart failur avail cardiolog survey januari
exhibit data obtain du et al natur review cardiolog estim incid heart failur hospit
rate base us censu du et al natur review cardiolog
heart failur inabl heart pump blood effici present either
impair eject blood systol heart failur defect ventricular fill
diastol heart failur associ fluid retent peripher tissu includ
lung lead tissu congest dyspnea fatigu ultim death heart
failur major unmet medic need lead world-wide caus
hospit elderli approxim million case annual unit
state accord du et al natur review cardiolog incid increas
age popul improv surviv rate myocardi infarct
lifetim risk develop heart failur one five relaxin develop
treat acut heart failur rapid onset heart failur result hospit
chronic heart failur long-term condit acut decompens heart failur
worsen chronic heart failur symptom result acut respiratori distress
hospit
acut heart failur occur heart suddenli pump enough blood meet
bodi demand common symptom short breath mani
symptom chronic sever heart failur leg abdomen may
suddenli swell one could rapidli gain weight retain fluid could mean
two three pound period five pound cours week one
may also experi nausea loss appetit symptom includ weak
fatigu irregular fast heartbeat cough wheez spit pink phlegm
decreas abil concentr type acut hear failur includ left right-sid
heart failur two type left-sid heart failur systol heart failur
common happen heart weak enlarg systol heart failur
muscl left ventricl unabl contract shorten prevent blood
pump effect bodi left-sid type diastol heart failur
occur blood unabl properli fill left ventricl heart
pump less blood bodi normal low blood flow like caus
ventricl stiffen right-sid heart failur usual happen simultan left-sid
heart failur failur left ventricl result increas pressur subsequ
damag right side heart prohibit right side heart
pump effici caus acut heart failur includ infect allerg reaction
blood clot lung virus damag heart cardiopulmonari bypass surgeri
sever irregular heartbeat heart attack
chronic heart failur congest heart failur chf chronic progress
condit affect pump power heart muscl chf specif refer
stage fluid build around heart caus pump ineffici
result fluid build around lung abdomen liver lower bodi systol heart failur
occur left ventricl fail contract normal reduc level forc
avail push blood circul without forc heart pump properli
diastol failur diastol dysfunct happen muscl left ventricl
becom stiff longer relax heart cant quit fill blood
beat four stage progress increas limit treatment
option chf worsen caus chf includ hypertens coronari arteri diseas
valv condit among heart-rel condit earlier stage patient may
experi symptom eventu includ fatigu weight gain short breath
edema chest pain respiratori issu current treatment option ace inhibitor
beta-block diuret surgeri
heart diseas lead caus death unit state account
approxim one everi four death coronari arteri diseas cad primari
caus ischem heart failur affect arteri provid blood suppli cardiac
muscl current treatment includ revascular coronari arteri reliev
symptom improv cardiac function therapi reduc blood pressur
potenti help elimin excess water congest tissu beta-block
blocker diuret howev adult human unabl regener myocardium
approv estim enter heart failur market
market penetr conserv estim achiev market
penetr set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim heart failur
set averag price per cours therapi per month use
entresto compar estim world-wide sale increas
billion howev pure oppenheim co estim
provid strategi price exhibit
exhibit estim world-wide sale grow billion
treatedheart failur per cours therapi failur increasessal thousand heart failur us relaxin sale ex-u relaxin sale ww relaxin sale compani data oppenheim co estimatesaddit inform avail upon request
intraven iv -administ mrna encod mut lipid
nanoparticl lnp design manufactur restor defici defect
mitochondri enzym liver caus isol methylmalon acidemia mma
investig two differ preclin mous model
receiv pediatr diseas design orphan drug design fda
orphan drug design european commiss
current develop treatment isol mma associ
mut defici
administ subcutan inject contain mrna encod
human mut encapsul lnp mrna-encod mut protein transloc
site action mitochondria preclin studi six-week repeat-dos
mg/kg weekli iv test
conduct preclin trial seri vitro vivo pharmacolog
studi two differ mous model mma repres spectrum mut
defici publish cell report
preclin studi six-week repeat-dos studi mma mice mg/kg iv
weekli show pronounc improv surviv due human mut mrna
treatment treat mice surviv durat studi contrast control
mice perish within week except one addit
treat mice gain weight compar sole surviv mous control
mrna group show signific sustain reduct toxic diseas
metabolit includ plasma methylmalon acid compar basal level
pharmacokinet studi perform wild-typ mice demonstr human mut
elev wild-typ mut level specif human mut protein express
liver peak hour singl iv inject human mut mrna mg/kg
concentr ng/mg protein approxim two- three-fold higher
endogen human mous mut liver
still experiment therapi therefor establish price base
similar mma gaucher diseas estim potenti price
base current price cerezym cost approxim
per year standard cours treatment oppenheim co
estim base avail price data dosag data cerezym prescript
expect initi phase i/ii clinic trial mma patient mut defici
current conduct global natur histori studi mma propion
acidemia pa plan initi phase i/ii clinic trial note
glp toxicolog studi complet mma current write ind fda
natur histori studi patient organ acidemia
sponsor longitudin exploratori natur histori studi patient
mma due mut defici patient pa character chang blood
diseas biomark time frequenc sever clinic event relat
diseas elig patient mma must confirm diagnosi isol
mma due mut defici mut- base elev plasma/serum/db
urin methylmalon acid level presenc normal serum/plasma vitamin
plasma homocystein level confirm genet test elig patient pa must
confirm diagnosi isol pa base elev plasma/dbs/urin
and/or elev plasma/serum/db propionylcarnitin confirm genet
outcom measur mma chang plasma methylmalon acid level
frequenc disease-rel clinic event enrol particip mut-
period month outcom measur pa chang plasma level
plasma level frequenc disease-rel clinic event enrol patient
period month studi design enrol patient initi
march estim primari complet date march
anticip publish data natur histori studi expect
inform phase trial design
plan phase i/ii dose-escal studi patient mma
plan conduct open-label multi-cent dose-escal phase i/ii studi
multipl ascend dose primarili pediatr patient isol mma
due mut defici primari object studi evalu safeti
toler administ via iv infus secondari object
studi assess pharmacodynam respons assess chang plasma
methylmalon acid primari metabolit accumul disord
character pharmacokinet profil assess frequenc
sever clinic event relationship plasma methylmalon acid phase
i/ii studi expect conduct unit state europ anticip
initi trial unit state first
awar patent specif file would
consist earli clinic stage develop howev identifi
patent protect platform technolog use discoveri
develop mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl
infring expir appendix
base data manoli sloan jl venditti cp isol methylmalon acidemia
genereview nation genom institut nhgri believ
total mma patient popul approxim us per year base
lower end rang sourc patient exhibit
incid preval estim mma deriv appli annual
estim growth rate popul
exhibit data obtain manoli sloan jl venditti cp isol methylmalon acidemia genereview nhgri
estim preval mma base us censu peer-review sourc
methylmalon acidemia mma autosom recess inherit inborn metabol
disord associ mut enzym defici mma character occurr
acut metabol decompens typic frequent first
year life decompens life-threaten often requir hospit
manag intens care unit surviv patient often suffer numer
complic includ chronic renal failur neurolog complic
movement disord development delay seizur consequ health-
relat qualiti life mma patient famili significantli impair mut
mitochondri enzym involv metabol certain protein fat result
complet partial mut- enzym defici report distribut
mut- patient accord data manoli sloan jl venditti cp
approv estim enter methylmalon acidemia
market market penetr conserv estim achiev
market penetr set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim mma set
averag price per cours therapi per month use cerezym
compar estim world-wide sale increas
million howev pure oppenheim co estim
provid strategi price exhibit
exhibit estim world-wide sale grow million
penetrationmethylmalon treatedmethylmalon per cours therapi increasessal thousand methylmalon us mma sale ex-u mma sale thousand ww mma sale compani data oppenheim co estimatesaddit inform avail upon request
intraven iv -administ mrna encod phenylalanin
hydroxylas pah protein liver encapsul lipid nanoparticl lnp
treatment phenylketonuria pku mrna sequenc optim protein
synthesi contain mrna bind site reduc potenti elimin synthesi
protein outsid target tissu studi preclin
current develop treatment pediatr pku
administ subcutan inject contain mrna mrna
encod human pah encapsul lnp preclin studi dose mg/kg
everi seven day test mice
still experiment therapi therefor establish price
estim potenti price could base current price palynziq
cost approxim per year standard cours treatment
oppenheim co estim base avail price data dosag data
palynziq prescript label
plan conduct phase open-label clinic trial singl ascend
dose evalu safeti toler activ develop candid
patient current conduct glp toxicolog studi anticip
file ind approxim six month initi toxicolog studi
preclin vitro vivo pharmacolog studi repeat dose
demonstr signific reduct phe blood level pku mous model
studi includ iv administr pah mrna everi seven day mg/kg pah
homozyg mutant -/- mice phe level measur use liquid chromatographi
combin two mass analyz lc-ms/m note believ
short durat effect mous model driven higher basal metabol rate
mice compar human higher protein intak recommend level
awar patent specif file would
consist preclin stage develop howev identifi
patent protect platform technolog use discoveri
develop mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl
infring expir appendix
base rang incid rate cite nation organ disord
nord rang total us popul approxim
accord censu data believ total us pku patient
popul approxim midpoint rang pku
patient us per year base incid rate cdc nation center
health statist estim newborn children annual us estim
approxim newborn diagnos pku us per year
exhibit data obtain nord estim preval pku base us censu nord
phenylketonuria pku rare inherit metabol diseas result defici
metabol phenylalanin phe due mutat within enzym
phenylalanin hydroxylas pah result reduc complet inabl
metabol essenti amino acid phenylalanin tyrosin caus pku patient
suffer phenylalanin intox subsequ depriv tyrosin lead
sever mental disabl left untreat diagnosi pku occur primarili
newborn screen avail countri follow genet confirm newli
diagnos patient receiv medic formula contain protein low phe content
control blood phe provid adequ nutrit grow infant
size phenylketonuria moderna
approv estim enter pku market
market penetr patient market penetr infant patient
conserv estim achiev market penetr patient
market penetr infant pku set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim all-pati
infant patient pku set averag price per cours therapi
per month use palynziq compar estim world-wide
sale increas billion howev pure oppenheim co
estim provid strategi price exhibit
exhibit estim world-wide sale grow billion
pku penetrationphenylketonuria treatedphenylketonuria per cours therapi increasessal us pku sale ex-u pku sale ww pku sale compani data oppenheim co estimatesaddit inform avail upon request outperform
intraven iv -administ combin mrna subunit
pcc pcca pccb encapsul lipid nanoparticl lnp treatment
propion acidemia pa mrna sequenc engin improv protein
translat encod enzymat activ pcc proper subcellular local
mitochondria investig preclin mous model
current develop treatment pediatr pa
administ subcutan inject contain mrna
subunit pcc pcca pccb encapsul lnp mrna encod
enzymatically-act pcc proper subcellular local mitochondria
preclin studi singl dose mg/kg iv test
still experiment therapi therefor establish price
estim potenti price base current price cerezym
cost approxim per year standard cours treatment
oppenheim co estim base avail price data dosag data
conduct seri preclin vitro vivo pharmacolog studi
preclin studi pcca pccb mrna transfect pa mice fibroblast
pcca pccb-defici show product activ pcc enzym proper
subcellular local mitochondria concentr wild-typ level vivo
studi pa pcca mice result dose-depend increas hepat pcc
activ concomit decreas diseas biomark note
reduct plasma ammonia level observ week singl iv
administr mg/kg pcca pccb mrna encapsul lnp pa mice
addit six-month repeat-dos studi pa mice show decreas
heart weight normal bodi weight mice treat monthli iv administr
pcca pccb mrna mg/kg compar control mrna also
observ signific sustain lower addit diseas biomark includ
throughout durat six-month studi
current conduct global natur histori studi mma pa
plan initi phase i/ii clinic trial pediatr pa patient natur histori
studi initi april expect complet march
current conduct glp toxicolog studi file ind complet
anticip file ind approxim within six month initi
natur histori studi patient organ acidemia
sponsor longitudin exploratori natur histori studi patient
mma result mut defici patient pa character chang
blood diseas biomark time frequenc sever clinic event
relat diseas elig patient mma must confirm diagnosi
isol mma due mut defici mut- base elev plasma/serum/
db urin methylmalon acid level presenc normal serum/plasma vitamin
plasma homocystein level confirm genet test elig pa patient
must confirm diagnosi isol pa base elev plasma/dbs/urin
mc and/or elev plasma/serum/db propionylcarnitin confirm
outcom measur mma chang plasma methylmalon acid level
frequenc disease-rel clinic event enrol particip mut-
period month outcom measur pa chang plasma level
plasma level frequenc disease-rel clinic event enrol patient
period month
studi design enrol patient initi march
estim primari complet date march
plan phase i/ii dose-escal studi patient pa
plan conduct open-label multi-cent dose-escal phase i/ii studi
multipl ascend dose pediatr patient pa unit state
europ primari object studi evalu safeti toler
administ via iv infus secondari object studi
assess pharmacodynam respons assess chang plasma biomark
character pharmacokinet profil assess frequenc
sever clinic event relationship plasma biomark level
current conduct glp toxicolog studi program anticip ind
file anticip data studi
awar patent specif file would
consist earli clinic stage develop howev identifi
patent protect platform technolog use discoveri
develop mrna therapeut forty-four patent expir date
addit patent in-licens avoid possibl
infring expir appendix
base preval peopl us cite nation institut
total us popul approxim accord us censu
data estim total pa patient popul estim approxim
us howev literatur sourc includ manoli sloan jl venditti cp
isol methylmalon acidemia genereview indic preval
base rang conserv estim us preval pa
exhibit data obtain manoli sloan jl venditti cp isol methylmalon acidemia genereview estim preval
pa base us censu peer-review sourc
propion acidemia pa autosom recess inherit inborn metabol
disord close relat mma signific morbid mortal similar mma
disord character occurr life-threaten acut metabol
decompens frequent first year life longer term
sequela includ cardiac complic cardiomyopathi arrhythmia sever
neurolog complic disord caus defect defici pcc
enzym one step upstream metabol pathway break certain
protein fat mut enzym defici mma pcc complex hetero-
dodecam enzym compos six alpha subunit pcca six beta subunit
pccb pa patient gener loss-of-funct mutat either pcca pccb
rare instanc similar mma due enzym defici result
metabol block disord biochem character accumul toxic
metabolit acid among other
may use biomark diseas
approv estim enter pa market
market penetr conserv estim achiev market
penetr set exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim pa set
averag price per cours therapi per month use cerezym
compar estim world-wide sale increas million
howev pure oppenheim co estim
provid strategi price exhibit
exhibit estim world-wide sale grow million
penetrationpropion treatedpropion per cours therapi increasessal thousand propion us pa sale ex-u pa sale ww pa sale compani data oppenheim co estimatesaddit inform avail upon request outperform
prophylact vaccin design manufactur treat prevent
chikungunya viru vaccin administ intramuscularli consist singl
mrna encod full nativ structur polyprotein natur
process protein assembl vlp releas cell
turn produc secret chikungunya virus-lik particl vlp induc
protect neutral antibodi respons program support
defens advanc research project agenc darpa phase trial us
met primari secondari object safeti toler plan
proceed phase ii studi pend govern grant fund
phase trial administ intramuscular
inject contain mrna encod entir chikungunya viru structur polyprotein
deliv cell via lipid nanoparticl lnp deliveri mechan phase
trial evalu three dose-level cohort two-dos inject
seri space four week apart june one grade solicit
ae cohort studi fulli enrol patient
initi august estim primari complet data march trial
on-going complet safeti follow-up measur persist
expect present follow-up data studi futur vaccin meet
preclin studi mice non-human primat nhp
observ induc robust neutral antibodi respons dose-
regimen- depend manner one- two-dos vaccin seri protect
mice lethal chikungunya viru challeng administ day later
chikungunya mosquito-born rna alphaviru origin africa recent
outbreak spread aed mosquito chikungunya epidem began
kenya spread india export nearli region world brought
chikungunya attent western world april chikungunya case
report countri territori world-wide includ countri
territori throughout america chikungunya viru caus diseas
character acut onset fever rash myalgia debilit polyarthralgia
deriv name mean bend translat
makond rare fatal neurolog sequela guillain-barr syndrom
chronic arthralgia associ infect viru alphaviru
togavirida famili positive-strand rna genom viral structur protein
natur express singl polyprotein follow subsequ cleavag viral
cellular proteas capsid envelop glycoprotein
 protein major target protect neutral antibodi respons
vaccin
prophylact vaccin prevent treatment
influenza encod cell membrane-bound viral
hemagglutinin ha protein strain avian influenza viru
respect conduct clinic trial vaccin
investig phase dose-rang studi germani met safeti toler
immunogen object current investig phase
dose-rang studi us preclin studi observ
vaccin demonstr immunogen ferret cynomolgu monkey
report journal molecular therapi also observ
vaccin demonstr immunogen cynomolgu monkey also report
journal molecular therapi
phase clinic trial germani administ intramuscular
inject dose level two-dos
vaccin schedul day day also administ intraderm
inject dose level two-dos vaccin schedul day
day note overal well toler
im dose trial initi decemb primari complet date
octob origin referenc
phase clinic trial us administ intramuscular
inject im dose level compar two two-dos
vaccin schedul day day vs day month note
well toler im dose trial initi may
primari complet date septemb origin
referenc
influenza rna viru genom pack eight individu gene segment
code least function protein need infect replic evas
host antivir respons two major glycoprotein express surfac
virion hemagglutinin ha neuraminidas na crucial
infect ha mediat viral entri host cell bind sialic acid contain
receptor host cell surfac caus fusion viral host endosom
membran na mediat enzymat cleavag viral receptor late stage
infect allow releas progeni virion influenza virus infect varieti
speci includ bird pig sea mammal human wild aquat bird serv
reservoir influenza virus infect avian mammalian speci although mani
virus non-pathogen bird infect human recent
decad avian influenza virus cross
speci barrier caus human diseas
prophylact vaccin design manufactur
treat prevent zika viru administ intramuscularli contain
sequenc encod prme structur protein zika viru intend design
translat polyprotein process insid cell make secret virus-
like particl vlp process mimic respons cell natur infect
origin addit altern identifi contain
mrna sequenc formul proprietari lipid
nanoparticl lnp deliveri mechan replac given
compar increas product zika vlp use distinct rna sequenc also
formul lnp preclin studi test
mice non-human primat nhp data publish journal cell
current evalu phase trial us plan
initi phase trial
administ intramuscular inject
phase studi evalu two-dos vaccin schedul
day apart three dose level august mrna-
observ vaccin well toler immunogen object dose
ug met despit safeti profil would permit addit dose
escal instead focus advanc contain
engin sequenc shown potent nhp primat zika challeng
studi phase trial design enrol particip initi
decemb primari estim complet date februari
believ may new glp toxicolog studi
advanc program phase ii trial
zika viru single-strand rna viru flavivirida famili first isol
rhesu macaqu zika forest uganda first human case
document seroepidemiolog data suggest endem region
africa asia aed mosquito vector found zika viru predominantli
spread mosquito aed genu also transmit congenit
sexual blood donat zika infect usual asymptomat mild
adult lead fever rash conjunct howev infect women
pregnanc result devast microcephali newborn microcephali birth
defect character abnorm small head brain associ lifelong
neurodevelopment delay seizur intellectu disabl balanc problem
dwarfism/short statur result signific disabl requir lifelong support
recent zika epidem estim price
zika vaccin could approxim us
methodolog collect patent inform
identifi patent drug preclin clinic develop
approv fda yet patent platform technolog sec
file search identifi assigne drug key term
compound name indic term associ platform technolog
search uspto websit identifi patent narrow
patent claim patent identifi relat patent could identifi
determin expir patent protect origin patent relat drug
identifi twenti year file origin patent patent protect
individu compani patent identifi narrow indic
exhibit patent data uspto continu
patent date file date present disclosur provid inter alia formul composit compris modifi nucleic acid molecul may encod protein protein precursor partial fulli process form protein protein precursor formul composit may includ modifi nucleic acid molecul deliveri agent present invent provid nucleic acid use encod polypeptid capabl modul cell function and/or present disclosur provid inter alia formul composit compris modifi nucleic acid molecul may encod protein protein precursor partial fulli process form protein protein precursor formul composit may includ modifi nucleic acid molecul deliveri agent present invent provid nucleic acid use encod polypeptid capabl modul cell function and/or present disclosur provid inter alia formul composit compris modifi nucleic acid molecul may encod protein protein precursor partial fulli process form protein protein precursor formul composit may includ modifi nucleic acid molecul deliveri agent present invent provid nucleic acid use encod polypeptid capabl modul cell function and/or composit method deliv biolog moieti modifi nucleic acid cell modul protein express composit method includ use modifi messeng rna use treat prevent diseas disord condit improv subject heath well present invent relat composit method kit use polynucleotid primari transcript mmrna invent relat composit method prepar manufactur therapeut use polynucleotid primari transcript mmrna invent relat composit method prepar manufactur therapeut use polynucleotid primari transcript mmrna invent relat composit method prepar manufactur therapeut use polynucleotid primari transcript mmrna invent relat composit method prepar manufactur therapeut use polynucleotid primari transcript mmrna invent relat composit method prepar manufactur therapeut use polynucleotid primari transcript mmrna invent relat composit method prepar manufactur therapeut use polynucleotid primari transcript mmrna invent relat composit method prepar manufactur therapeut use polynucleotid primari transcript mmrna molecul uspto
